{"content":"<li class=\"n-box-item date-title\" data-end=\"1521604799\" data-start=\"1521518400\" data-txt=\"Monday, December 23, 2019\">Tuesday, March 20, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3340603\" data-ts=\"1521591316\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340603-proteostatis-therapeutics-pulls-9m-share-offering-on-market-conditions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Proteostatis Therapeutics pulls 9M-share offering on market conditions</a></h4><ul>   <li>Proteostatis Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>) has <a href=\"https://seekingalpha.com/pr/17107809-proteostasis-therapeutics-announces-withdrawal-equity-offering-due-market-conditions\" target=\"_blank\">withdrawn a planned 9M-share offering</a>.</li>    <li>The company had <a href=\"https://seekingalpha.com/news/3340266-proteostasis-launches-9m-share-stock-offering\" target=\"_blank\">announced the offering</a> yesterday, but isn't proceeding due to market conditions that \"are not conducive for an offering on terms that would be in the best interest of its current stockholders.\"</li>    <li>Shares had <font color='red'>tumbled 26.2%</font> during market hours; they're <font color='green'>up 4.7%</font> postmarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340603\" data-linked=\"Proteostatis Therapeutics pulls 9M-share offering on market conditions\" data-tweet=\"$PTI - Proteostatis Therapeutics pulls 9M-share offering on market conditions https://seekingalpha.com/news/3340603-proteostatis-therapeutics-pulls-9m-share-offering-on-market-conditions?source=tweet\" data-url=\"https://seekingalpha.com/news/3340603-proteostatis-therapeutics-pulls-9m-share-offering-on-market-conditions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>11&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340602\" data-ts=\"1521588159\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTDOY\" target=\"_blank\">NTDOY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340602-videogame-sales-build-on-2018-23-february-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Videogame sales build on 2018 with 23% February gains</a></h4><ul>   <li>Videogame sales rose 23% in February, with continuing strong hardware gains making up for a flat month among game titles.</li>    <li>Overall sales came to $995M vs. a year-ago $811M, according to NPD Group. Hardware sales jumped 55% to $316M; software sales were flat at $397M (same as last February); and accessories rose 35% to $282M.</li>    <li>Combined with the <a href=\"https://seekingalpha.com/news/3333080-videogame-sales-jump-59-percent-best-january-seven-years\" target=\"_blank\">best January in seven years</a>, the month brought YTD overall videogame gains to 39% ($2.1B total).</li>    <li>Hardware sales are up 79% YTD, with Feburary gains driven by continuing growth in Nintendo Switch (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>) and in Xbox One (NASDAQ:<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a>). Sony's (NYSE:<a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a>) PlayStation 4 was the best-selling individual console, while the Switch has hit the highest installed base for a console's first 12 months, analyst Mat Piscatella notes.</li>    <li>In software, it was growth in Switch titles that offset declines elsewhere. <i>Monster Hunter: World</i> (<a href='https://seekingalpha.com/symbol/CCOEY' title='Capcom Co. Ltd ADR'>OTCPK:CCOEY</a>) repeated at the top spot in dollar sales, followed by <i>Call of Duty: WWII</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a>) and <i>NBA 2K18</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>). <i>Dragon Ball: Fighterz</i> (<a href='https://seekingalpha.com/symbol/NCBDF' title='Bandai Namco Holdings, Inc.'>OTCPK:NCBDF</a>) fell from the No. 2 spot to fourth, just ahead of <i>Grand Theft Auto V</i> (<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) which is hanging around at No. 5.</li>    <li>Rounding out the software top 10: No. 6, <i>UFC 3</i> (NASDAQ:<a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a>); No. 7, <i>Kingdom Come: Deliverance</i> (Deep Silver); No. 8, <i>Mario Kart 8</i> (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>); No. 9, <i>Super Mario Odyssey</i> (<a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a>); No. 10, <i>Tom Clancy's Rainbow Six: Siege</i> (<a href='https://seekingalpha.com/symbol/UBSFY' title='UbiSoft Entertainment Inc. ADR'>OTCPK:UBSFY</a>).</li>    <li>After hours: <a href='https://seekingalpha.com/symbol/NTDOY' title='Nintendo Co., Ltd. ADR'>OTCPK:NTDOY</a> flat; <a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> flat; <a href='https://seekingalpha.com/symbol/SNE' title='Sony Corporation'>SNE</a> <font color='green'>+0.7%</font>; <a href='https://seekingalpha.com/symbol/CCOEY' title='Capcom Co. Ltd ADR'>OTCPK:CCOEY</a> inactive; <a href='https://seekingalpha.com/symbol/ATVI' title='Activision Blizzard, Inc'>ATVI</a> flat; <a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> <font color='green'>+2%</font>; <a href='https://seekingalpha.com/symbol/NCBDF' title='Bandai Namco Holdings, Inc.'>OTCPK:NCBDF</a> inactive; <a href='https://seekingalpha.com/symbol/EA' title='Electronic Arts Inc.'>EA</a> flat; <a href='https://seekingalpha.com/symbol/UBSFY' title='UbiSoft Entertainment Inc. ADR'>OTCPK:UBSFY</a> inactive.</li>    <li>ETF: <a href='https://seekingalpha.com/symbol/GAMR' title='PureFunds Video Game Tech ETF'>GAMR</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3340602\" data-linked=\"Videogame sales build on 2018 with 23% February gains\" data-tweet=\"$NTDOY $NTDOY $MSFT - Videogame sales build on 2018 with 23% February gains https://seekingalpha.com/news/3340602-videogame-sales-build-on-2018-23-february-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3340602-videogame-sales-build-on-2018-23-february-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340594\" data-ts=\"1521584226\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIR\" target=\"_blank\">AIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340594-aarminus-3_6-revenues-miss-despite-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAR -3.6% as revenues miss despite growth</a></h4><ul>   <li>AAR (NYSE:<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corporation'>AIR</a>) is <font color='red'>3.6% lower</font> postmarket after its <a href=\"https://seekingalpha.com/news/3340531-aar-beats-0_01-misses-revenue\" target=\"_blank\">Q3 revenues</a> missed expectations despite double-digit growth.</li>    <li>Net income increased (to $15.5M from $13.7M) thanks in large part to an income tax benefit of $9.8M, vs. a year-ago expense of $7.7M. The company also took a loss of $15.8M from discontinued operations, as it's looking to sell its contractor-owned, contractor-operated &#40;COCO&#41; business.</li>    <li>Sales by segment: Aviation Services, $426.4M (up 11.3%); Expeditionary Services, $29.9M (up 22.5%).</li>    <li>Gross profit by segment: Aviation Services, $71.7M (up 12.5%); Expeditionary Services, $5.9M (up 79%).</li>    <li>Cash flow from operations was $50.3M; new accounts receivable financing contributed $52.3M.</li>    <li>It's affirmed in-line guidance for 2019 of sales of $2.1B-$2.2B (vs. consensus for $2.198B), EPS of $2.50-$2.80 (vs. consensus for $2.71), and EBITDA of $180M-$190M (vs. consensus for $186.9M).</li>    <li><a href=\"https://seekingalpha.com/pr/17107606-aar-reports-third-quarter-fiscal-year-2018-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3340594\" data-linked=\"AAR -3.6% as revenues miss despite growth\" data-tweet=\"$AIR - AAR -3.6% as revenues miss despite growth https://seekingalpha.com/news/3340594-aarminus-3_6-revenues-miss-despite-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3340594-aarminus-3_6-revenues-miss-despite-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340593\" data-ts=\"1521583932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JWN\" target=\"_blank\">JWN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340593-nordstromminus-4_8-company-breaks-off-go-private-talks-family\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nordstrom -4.8% as company breaks off go-private talks with family</a></h4><ul>   <li>The special board committee at Nordstrom (NYSE:<a href='https://seekingalpha.com/symbol/JWN' title='Nordstrom Inc.'>JWN</a>) says it's <a href=\"https://seekingalpha.com/pr/17107765-special-committee-nordstrom-board-terminates-discussions-nordstrom-family-group-regarding\" target=\"_blank\">broken off talks</a> with the Nordstrom family over taking the company private.</li>    <li>Shares are <font color='red'>down 4.8%</font> after hours.</li>    <li>The committee says it couldn't reach agreement on an acceptable price with the family group, which includes Co-Presidents Blake Nordstrom, Peter Nordstrom, and Erik Nordstrom; President of Stores James Nordstrom; Chairman Emeritus Bruce Nordstrom; and Anne E. Gittinger.</li>    <li>\"The Special Committee believes that Nordstrom is well positioned to capitalize on future opportunities to gain market share through its customer strategy, centered on three strategic pillars: providing a differentiated product offering; delivering exceptional services and experiences; and leveraging the strength of its brand,\" the committee says in its statement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340593\" data-linked=\"Nordstrom -4.8% as company breaks off go-private talks with family\" data-tweet=\"$JWN - Nordstrom -4.8% as company breaks off go-private talks with family https://seekingalpha.com/news/3340593-nordstromminus-4_8-company-breaks-off-go-private-talks-family?source=tweet\" data-url=\"https://seekingalpha.com/news/3340593-nordstromminus-4_8-company-breaks-off-go-private-talks-family\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340588\" data-ts=\"1521581726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340588-after-hours-gainers-losers-3-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (3/20/2018)</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a> <font color='green'>+20.5%</font>. <a href='https://seekingalpha.com/symbol/KEP' title='Korea Electric Power Corporation'>KEP</a> <font color='green'>+7.7%</font>. <a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a> <font color='green'>+4.6%</font>. <a href='https://seekingalpha.com/symbol/LAUR' title='Laureate Education'>LAUR</a> <font color='green'>+4.5%</font>. <a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color='green'>+3.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/TSLX' title='TPG Specialty Lending'>TSLX</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/AIR' title='AAR Corporation'>AIR</a> <font color='red'>-3.5%</font>. <a href='https://seekingalpha.com/symbol/DBVT' title='DBV Technologies'>DBVT</a> <font color='red'>-3.4%</font>. <a href='https://seekingalpha.com/symbol/AMTX' title='Aemetis, Inc.'>AMTX</a> <font color='red'>-3.3%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340588\" data-linked=\"After Hours Gainers / Losers (3/20/2018)\" data-tweet=\"$PRTA $PRTA $KEP - After Hours Gainers / Losers (3/20/2018) https://seekingalpha.com/news/3340588-after-hours-gainers-losers-3-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340588-after-hours-gainers-losers-3-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340568\" data-ts=\"1521579022\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRTA\" target=\"_blank\">PRTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340568-prothena-teams-up-celgene-in-neurodegenerative-disorders-shares-ahead-15-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Prothena teams up with Celgene in neurodegenerative disorders; shares ahead 15% after hours</a></h4><ul><li>Prothena (NASDAQ:<a href='https://seekingalpha.com/symbol/PRTA' title='Prothena Corp plc'>PRTA</a>) is up&nbsp;<font color='green'>15%</font>&nbsp;after hours on average volume in response to its <a href=\"https://seekingalpha.com/pr/17107636-prothena-announces-global-neuroscience-research-and-development-collaboration-celgene-novel\" target=\"_blank\">announcement </a>of a global collaboration with Celgene (<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a> <font color='red'>-0.3%</font>) aimed at developing new therapies for neurodegenerative diseases.</li><li>The partnership will focus on three proteins implicated in the pathogenesis of neurodegenerative disorders: tau, TDP-43 and an unnamed target. Celgene has the exclusive right to license the candidates in the U.S. at the IND stage and has the option to acquire global rights after Phase 1. If it elects to do so, it will be responsible for funding all further clinical development and commercialization.</li><li>Under the terms of the agreement, Prothena will receive $100M upfront, a $50M equity investment (~1.2M shares at $42.57) by Celgene, potential exercise payments, milestones and royalties on net sales.</li><li>Prothena will host a conference call at 5:00 pm ET to discuss the collaboration.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340568\" data-linked=\"Prothena teams up with Celgene in neurodegenerative disorders; shares ahead 15% after hours\" data-tweet=\"$PRTA $PRTA $CELG - Prothena teams up with Celgene in neurodegenerative disorders; shares ahead 15% after hours https://seekingalpha.com/news/3340568-prothena-teams-up-celgene-in-neurodegenerative-disorders-shares-ahead-15-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3340568-prothena-teams-up-celgene-in-neurodegenerative-disorders-shares-ahead-15-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>29&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340500\" data-ts=\"1521578829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GBTC\" target=\"_blank\">GBTC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340500-alt-coin-bear-market-ended-according-to-bull-tom-lee\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alt-coin bear market has ended, according to bull Tom Lee</a></h4><ul>     <li>With increasing regulatory crackdowns and a ban on web advertising of ICOs, the outlook for major digital currencies remains uncertain, but <a href=\"https://www.marketwatch.com/story/bitcoin-holds-steady-as-one-analyst-calls-the-end-to-alt-coin-bear-market-2018-03-20\" target=\"_blank\">Tom Lee of Fundstrat thinks otherwise.</a></li>     <li>&ldquo;We believe the bear market is over, because our preferred measure [the percent of alt-coin stocks that have risen by more than 3X in the past 90 days] is back down to 3%. This is historically the level at which alt-coin bear markets typically bottom,&rdquo; wrote Lee.</li>     <li>Lee thinks the selling may be over, but it will be a few more months before it's ripe to buy again. &ldquo;In our view, given the overhang from SEC actions (potential to require tokens to be registered) and the potential backlash from Washington, we think mid-September is probably the more correct window,&rdquo; Lee wrote.</li>     <li>Digital tokens are recovering as Bitcoin touched a high above $9,000, and is up more than 6.5% in the last 24 hours according to <a href=\"https://coinmarketcap.com/\" target=\"_blank\">Coinmarketcap</a>. Ethereum is up&nbsp;4% to $564, Bitcoin-Cash is at $1,061, up 10%, Litecoin is&nbsp;up 10%&nbsp;to $171, and Ripple&nbsp;is up 5%&nbsp;to $0.72.</li>     <li>Related tickers: <a href='https://seekingalpha.com/symbol/GBTC' title='Grayscale Bitcoin Trust &#40;BTC&#41;'>OTCQX:GBTC</a>, <a href='https://seekingalpha.com/symbol/COIN' title='Winklevoss Bitcoin Trust ETF'>COIN</a>, <a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>, <a href='https://seekingalpha.com/symbol/OSTK' title='Overstock.com, Inc.'>OSTK</a>, <a href='https://seekingalpha.com/symbol/SSC-OLD' title='Seven Stars Cloud Group, Inc.'>SSC-OLD</a>, <a href='https://seekingalpha.com/symbol/MARA' title='Marathon Patent Group, Inc.'>MARA</a>, <a href='https://seekingalpha.com/symbol/UEPS' title='Net 1 UEPS Technologies, Inc.'>UEPS</a>, <a href='https://seekingalpha.com/symbol/BITCF' title='First Bitcoin Capital Corp.'>OTC:BITCF</a>, <a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>, <a href='https://seekingalpha.com/symbol/GROW' title='U.S. Global Investors, Inc.'>GROW</a>, <a href='https://seekingalpha.com/symbol/BTSC' title='Bitcoin Services, Inc.'>OTCPK:BTSC</a>, <a href='https://seekingalpha.com/symbol/BTCS' title='BTCS Inc.'>OTCQB:BTCS</a>, <a href='https://seekingalpha.com/symbol/MGTI' title='MGT Capital Investments, Inc.'>OTCQB:MGTI</a>, <a href='https://seekingalpha.com/symbol/BTLLF' title='Interbit Ltd.'>OTCPK:BTLLF</a> <a href='https://seekingalpha.com/symbol/SRAX' title='Social Reality Inc.'>SRAX</a>, <a href='https://seekingalpha.com/symbol/GAHC' title='Global Arena Holding, Inc.'>OTCPK:GAHC</a>, <a href='https://seekingalpha.com/symbol/ARSC' title='American Security Resources Corp.'>OTC:ARSC</a>, <a href='https://seekingalpha.com/symbol/USTC' title='USA Real Estate Holding Co'>OTCPK:USTC</a>, <a href='https://seekingalpha.com/symbol/BLKCF' title='Global Blockchain Technologies Corp.'>OTCPK:BLKCF</a>, <a href='https://seekingalpha.com/symbol/COINB' title='Coinbase'>COINB</a>, <a href='https://seekingalpha.com/symbol/LFIN' title='LongFin Corp.A'>OTCPK:LFIN</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3340500\" data-linked=\"Alt-coin bear market has ended, according to bull Tom Lee\" data-tweet=\"$GBTC $GBTC $COIN - Alt-coin bear market has ended, according to bull Tom Lee https://seekingalpha.com/news/3340500-alt-coin-bear-market-ended-according-to-bull-tom-lee?source=tweet\" data-url=\"https://seekingalpha.com/news/3340500-alt-coin-bear-market-ended-according-to-bull-tom-lee\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340566\" data-ts=\"1521578614\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CRM\" target=\"_blank\">CRM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340566-salesforce-buys-mulesoft-for-44_89-per-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Salesforce buys MuleSoft for $44.89 per share</a></h4><ul><li>        Salesforce (NYSE:<a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a>) <a href=\"https://www.prnewswire.com/news-releases/salesforce-signs-definitive-agreement-to-acquire-mulesoft-300617056.html\" target=\"_blank\">will acquire</a> MuleSoft (NYSE:<a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a>) for an enterprise value of about $6.5B.</li><li>               Salesforce will pay $36 in cash and 0.0711 shares of Salesforce common stock per MuleSoft Class A and Class B price.&nbsp;</li><li>               Total per share price adds up to $44.89, a 36% premium on yesterday&rsquo;s closing price.&nbsp;</li><li>               Salesforce expects the deal to close in its Q2.&nbsp;</li><li>               Salesforce shares are&nbsp;<font color='red'>down 3%</font>&nbsp;aftermarket.&nbsp;</li><li>                  MuleSoft shares are&nbsp;<font color='green'>up 3.5%</font>&nbsp;after closing the day&nbsp;<font color='green'>up 27.2%</font>.&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3340479-mulesoft-plus-22_4-percent-acquisition-target-news\" target=\"_blank\">MuleSoft +22.4% on acquisition target news</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340566\" data-linked=\"Salesforce buys MuleSoft for $44.89 per share\" data-tweet=\"$CRM $CRM $MULE - Salesforce buys MuleSoft for $44.89 per share https://seekingalpha.com/news/3340566-salesforce-buys-mulesoft-for-44_89-per-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3340566-salesforce-buys-mulesoft-for-44_89-per-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:43 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340561\" data-ts=\"1521578232\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBBP\" target=\"_blank\">SBBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340561-strongbridge-pharma-nabs-u-s-patent-covering-levoketoconazole-for-cushings-syndrome-shares-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Strongbridge Pharma nabs U.S. patent covering levoketoconazole for Cushing&#39;s syndrome; shares up 2% after hours</a></h4><ul><li>The USPTO has issued <a href=\"https://seekingalpha.com/pr/17107646-strongbridge-biopharma-announces-issuance-patent-recorlev-levoketoconazole-treatment-cushing\" target=\"_blank\">Patent No. 9,918,984</a> to Strongbridge Biopharma plc (NASDAQ:<a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a>) covering methods and compositions for treating diabetes, metabolic syndrome and other conditions. The claims are directed towards the treatment of Cushing's syndrome with levoketoconazole. The patent will in effect until January 10, 2026.</li><li>Shares are up&nbsp;<font color='green'>2%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340561\" data-linked=\"Strongbridge Pharma nabs U.S. patent covering levoketoconazole for Cushing&#39;s syndrome; shares up 2% after hours\" data-tweet=\"$SBBP - Strongbridge Pharma nabs U.S. patent covering levoketoconazole for Cushing&#39;s syndrome; shares up 2% after hours https://seekingalpha.com/news/3340561-strongbridge-pharma-nabs-u-s-patent-covering-levoketoconazole-for-cushings-syndrome-shares-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3340561-strongbridge-pharma-nabs-u-s-patent-covering-levoketoconazole-for-cushings-syndrome-shares-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:37 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340559\" data-ts=\"1521577966\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340559-amd-will-fix-security-issues-firmware-patches\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD will fix security issues with firmware patches</a></h4><ul><li>AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) will release a series of firmware patches in the coming weeks to address the recently disclosed security issues.</li><li>The processor issues first came to light through a white paper from security firm CTS-Labs, which gave AMD less than a day to respond to the findings.</li><li>AMD now acknowledges the problems for the first time but says that an attacker would have to gain administrative access to the system to take advantage of the flaws.</li><li>AMD doesn&rsquo;t expect the patches to impact performance.</li><li>Read more about the fixes and the problem at AMD&rsquo;s <a href=\"https://community.amd.com/community/amd-corporate/blog/2018/03/20/initial-amd-technical-assessment-of-cts-labs-research\" target=\"_blank\">blog</a>.</li><li>AMD shares closed the day&nbsp;<font color='red'>down 2.8%</font>&nbsp;but are now&nbsp;<font color='green'>up 1.1%</font>&nbsp;aftermarket.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338753-cnet-researchers-find-13-vulnerabilities-amd-chips\" target=\"_blank\">CNET: Researchers find 13 vulnerabilities in AMD chips</a> (March 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338831-amds-statement-alleged-chip-flaws\" target=\"_blank\">AMD's statement on alleged chip flaws</a> (March 13)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338900-research-firm-behind-amd-chip-flaw-reveal\" target=\"_blank\">More on the research firm behind the AMD chip flaw reveal</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340559\" data-linked=\"AMD will fix security issues with firmware patches\" data-tweet=\"$AMD - AMD will fix security issues with firmware patches https://seekingalpha.com/news/3340559-amd-will-fix-security-issues-firmware-patches?source=tweet\" data-url=\"https://seekingalpha.com/news/3340559-amd-will-fix-security-issues-firmware-patches\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:32 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>86&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340554\" data-ts=\"1521577850\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALDR\" target=\"_blank\">ALDR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340554-alder-bio-steps-down-shares-up-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alder Bio steps down, shares up 1% after hours</a></h4><ul><li>Alder BioPharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ALDR' title='Alder Biopharmaceuticals Inc.'>ALDR</a>) <a href=\"https://seekingalpha.com/pr/17107634-alder-biopharmaceuticals-appoints-paul-b-cleveland-interim-president-chief-executive-officer\" target=\"_blank\">appoints </a>board member Paul Cleveland as interim President &amp; CEO effective immediately. He replaces Randall Schatzman who will step down. A search has been initiated for a permanent successor.</li><li>Shares are up&nbsp;<font color='green'>1%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340554\" data-linked=\"Alder Bio steps down, shares up 1% after hours\" data-tweet=\"$ALDR - Alder Bio steps down, shares up 1% after hours https://seekingalpha.com/news/3340554-alder-bio-steps-down-shares-up-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3340554-alder-bio-steps-down-shares-up-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340552\" data-ts=\"1521577595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340552-fedexplus-2_6-revenue-boost-fuel-impact-drives-profit-gains\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx +2.6% as revenue boost, fuel impact drives profit gains</a></h4><ul>   <li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) is <font color='green'>up 2.6%</font> postmarket after double-digit revenue growth paced a healthy beat on top and bottom lines in <a href=\"https://seekingalpha.com/news/3340542-fedex-beats-0_61-beats-revenue\" target=\"_blank\">fiscal Q3 earnings</a>.</li>       <li>Revenues grew 10% to $16.5B; operating income ticked up to $1.11B from $1.1B. Operating margin fell to 6.4% from 7.4%.</li>    <li>Net income, meanwhile, grew 63% to $1.02B, excluding a $1.15B reduction in deferred tax liability (on an as-reported basis, net income rose from $562M a year ago to $2.07B for the current quarter).</li>    <li>The company saw higher base rates, increased volume at FedEx Ground and FedEx Freight, and favorable fuel impact.</li>    <li>&ldquo;Execution of our long-term growth strategies, customer demand for the unique value of our broad portfolio of solutions and healthy growth in the global economy are driving our performance,&rdquo; says CEO Frederick Smith.</li>    <li>For Q4, it's guiding to adjusted operating income of $1.95B-$2.05B (excluding TNT Express integration expenses). For fiscal 2018, it's guiding to adjusted EPS of $15.00-$15.40 (adjusting for remeasurement of deferred tax liability).</li>    <li><a href=\"https://event.on24.com/eventRegistration/EventLobbyServlet?target=registration.jsp&amp;eventid=1625000&amp;sessionid=1&amp;key=E62195DA0ADA172D1C2A4DE30A7EE7DB&amp;sourcepage=register\" target=\"_blank\">Conference call</a> to come at 5 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17107643-fedex-corp-reports-third-quarter-earnings\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3340552\" data-linked=\"FedEx +2.6% as revenue boost, fuel impact drives profit gains\" data-tweet=\"$FDX - FedEx +2.6% as revenue boost, fuel impact drives profit gains https://seekingalpha.com/news/3340552-fedexplus-2_6-revenue-boost-fuel-impact-drives-profit-gains?source=tweet\" data-url=\"https://seekingalpha.com/news/3340552-fedexplus-2_6-revenue-boost-fuel-impact-drives-profit-gains\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340551\" data-ts=\"1521577590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340551-arena-pharma-launches-7_5m-share-stock-offering-shares-off-1-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena Pharma launches 7.5M-share stock offering; shares off 1% after hours</a></h4><ul><li>Arena Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) <a href=\"https://seekingalpha.com/pr/17107605-arena-pharmaceuticals-announces-proposed-public-offering-common-stock\" target=\"_blank\">launches </a>a public offering of 7.5M shares of common stock. Price and terms have yet to be announced. Shares are down&nbsp;<font color='red'>1%</font>&nbsp;after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340551\" data-linked=\"Arena Pharma launches 7.5M-share stock offering; shares off 1% after hours\" data-tweet=\"$ARNA - Arena Pharma launches 7.5M-share stock offering; shares off 1% after hours https://seekingalpha.com/news/3340551-arena-pharma-launches-7_5m-share-stock-offering-shares-off-1-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3340551-arena-pharma-launches-7_5m-share-stock-offering-shares-off-1-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340542\" data-ts=\"1521577000\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340542-fedex-beats-0_61-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx beats by $0.61, beats on revenue</a></h4><ul><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>): Q3 EPS of $3.72 <font color='green'>beats by $0.61</font>.</li><li>Revenue of $16.5B (+10.0% Y/Y) <font color='green'>beats by $350M</font>.</li><li>Shares <font color='green'>+1.1%</font>.</li><li><a href='https://seekingalpha.com/pr/17107643-fedex-corp-reports-third-quarter-earnings'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3340542\" data-linked=\"FedEx beats by $0.61, beats on revenue\" data-tweet=\"$FDX - FedEx beats by $0.61, beats on revenue https://seekingalpha.com/news/3340542-fedex-beats-0_61-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3340542-fedex-beats-0_61-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340539\" data-ts=\"1521576901\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UQM\" target=\"_blank\">UQM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340539-uqm-technologiesplus-6_6-reports-trimming-losses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">UQM Technologies +6.6% as it reports trimming losses</a></h4><ul>   <li>UQM Technologies (NYSEMKT:<a href='https://seekingalpha.com/symbol/UQM' title='UQM Technologies, Inc'>UQM</a>) is <font color='green'>up 6.6%</font> in early postmarket trading after <a href=\"https://seekingalpha.com/news/3340532-uqm-technologies-reports-q4-results\" target=\"_blank\">Q4 earnings</a> where revenues grew nearly 30% and the company substantially trimmed losses.</li>    <li>For the year, cost of product sales were trimmed by more than half (to $4.37M), and the company cut more than $1M from R&amp;D spending.</li>    <li>Operating loss for 2017 was $5.28M, down from 2016's loss of $13.95M. Net loss for 2017 was $4.78M, vs. 2016's net loss of $13.95M.</li>    <li>Revenue breakout: Product sales, $1.22M; Contract services, $285,493.</li>    <li>On 2017: \"We saw good revenue growth, we secured a strategic relationship with China National Heavy Truck Group Co., Ltd., we made excellent progress with the E-axle product in partnership with Meritor, and we secured a number of new customers from around the globe,\" says CEO Joe Mitchell.</li>    <li><a href=\"https://event.on24.com/eventRegistration/EventLobbyServlet?target=reg20.jsp&amp;referrer=https%3A%2F%2Fwww.google.com%2Furl%3Fq%3Dhttps%253A%252F%252Fevent.on24.com%252Fwcc%252Fr%252F1553527%252FA6437EF5AD24468311B0F7BC659F07BB%26sa%3DD%26usd%3D2%26usg%3DAFQjCNELip2Uje5N8KU5qgHjUyz-mZmy9Q&amp;eventid=1553527&amp;sessionid=1&amp;key=A6437EF5AD24468311B0F7BC659F07BB&amp;regTag=&amp;sourcepage=register\" target=\"_blank\">Conference call</a> to come at 4:30 p.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/17107614-uqm-technologies-reports-quarter-fiscal-year-ended-december-31-2017-operating-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3340539\" data-linked=\"UQM Technologies +6.6% as it reports trimming losses\" data-tweet=\"$UQM - UQM Technologies +6.6% as it reports trimming losses https://seekingalpha.com/news/3340539-uqm-technologiesplus-6_6-reports-trimming-losses?source=tweet\" data-url=\"https://seekingalpha.com/news/3340539-uqm-technologiesplus-6_6-reports-trimming-losses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340533\" data-ts=\"1521576374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LUNA\" target=\"_blank\">LUNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340533-luna-innovations-misses-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Luna Innovations misses by $0.01, beats on revenue</a></h4><ul><li>Luna Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/LUNA' title='Luna Innovations Incorporated'>LUNA</a>): Q4 EPS of $0.01 <font color='red'>misses by $0.01</font>.</li><li>Revenue of $13.22M (-17.2% Y/Y) <font color='green'>beats by $1.42M</font>.</li><li>Shares <font color='green'>+2.77%</font>.</li><li><a href='https://seekingalpha.com/pr/17107594-luna-innovations-reports-strong-fourth-quarter-full-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3340533\" data-linked=\"Luna Innovations misses by $0.01, beats on revenue\" data-tweet=\"$LUNA - Luna Innovations misses by $0.01, beats on revenue https://seekingalpha.com/news/3340533-luna-innovations-misses-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3340533-luna-innovations-misses-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340526\" data-ts=\"1521574741\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FRESH\" target=\"_blank\">FRESH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340526-blue-apronminus-4_2-hellofresh-buys-rival\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blue Apron -4.2% as HelloFresh buys rival</a></h4><ul><li>           HelloFresh (<a href='https://seekingalpha.com/symbol/FRESH' title='HelloFresh'>FRESH</a>) <a href=\"https://www.reuters.com/article/greenchef-ma-hellofresh/hellofresh-to-buy-u-s-organic-meals-rival-green-chef-idUSASO0002BL?feedType=RSS&amp;feedName=companyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29\" target=\"_blank\">buys</a> rival meal-kit delivery company Green Chef Corporation for an undisclosed amount. </li><li> HelloFresh says the acquisition will contribute about $15M a quarter to revenue starting in Q2. But the deal will decrease core profit margin by 2 percentage points a quarter this year and will be broadly neutral to margin next year. </li><li> The acquisition could help HelloFresh achieve its goal of breaking even by the end of 2018. </li><li> Shares of struggling competitor Blue Apron (NYSE:<a href='https://seekingalpha.com/symbol/APRN' title='Blue Apron Holdings, Inc.'>APRN</a>)&nbsp;<font color='red'>drop 4.2%</font>&nbsp;to $2.08.&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3340526\" data-linked=\"Blue Apron -4.2% as HelloFresh buys rival\" data-tweet=\"$FRESH $FRESH $APRN - Blue Apron -4.2% as HelloFresh buys rival https://seekingalpha.com/news/3340526-blue-apronminus-4_2-hellofresh-buys-rival?source=tweet\" data-url=\"https://seekingalpha.com/news/3340526-blue-apronminus-4_2-hellofresh-buys-rival\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340525\" data-ts=\"1521574546\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ELSE\" target=\"_blank\">ELSE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340525-electro-sensors-reports-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electro-Sensors reports FY results</a></h4><ul><li>Electro-Sensors (NASDAQ:<a href='https://seekingalpha.com/symbol/ELSE' title='Electro-Sensors, Inc.'>ELSE</a>): FY EPS of $0.09</li><li>Revenue of $7.84M (+9.3% Y/Y)</li><li>Shares <font color='green'>+10.72%</font>.</li><li><a href='https://seekingalpha.com/pr/17107563-electro-sensors-inc-announces-2017-year-end-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3340525\" data-linked=\"Electro-Sensors reports FY results\" data-tweet=\"$ELSE - Electro-Sensors reports FY results https://seekingalpha.com/news/3340525-electro-sensors-reports-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3340525-electro-sensors-reports-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340524\" data-ts=\"1521574473\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340524-report-zuckerberg-sandberg-skip-facebook-employee-meeting\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Zuckerberg, Sandberg skip Facebook employee meeting</a></h4><ul>   <li>With criticism swelling about the lack of a public statement from Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) CEO Mark Zuckerberg on the Cambridge Analytica scandal, the company held an open employee meeting today to discuss the matter, but <a href=\"https://www.thedailybeast.com/exclusive-mark-zuckerberg-awol-from-facebooks-data-leak-damage-control-session\" target=\"_blank\">neither Zuckerberg nor Chief Operating Officer Sheryl Sandberg</a> attended, the Daily Beast reports.</li>    <li>Today's meeting was planned to be led by Deputy General Counsel Paul Grewal but Zuckerberg's potential participation today wasn't clear; Zuckerberg is expected to lead a meeting on Friday.</li>    <li>Shares are off session lows, now <font color='red'>down just 3.5%</font>.</li>    <li>&ldquo;Mark, Sheryl and their teams are working around the clock to get all the facts and take the appropriate action moving forward, because they understand the seriousness of this issue,\" a Facebook spokesperson told the Daily Beast.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340484-facebook-social-peers-keep-sinking-spiraling-regulatory-news-updated\" target=\"_blank\">Facebook and social peers keep sinking on spiraling regulatory news (updated)</a> (Mar. 20 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340437-facebook-minus-2_7-percent-report-ftc-investigating-data-issue\" target=\"_blank\">Facebook -2.7% on report FTC is investigating data issue</a> (Mar. 20 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340394-facebook-plans-staff-meeting-today-discuss-data-scandal\" target=\"_blank\">Facebook plans staff meeting today to discuss data scandal</a> (Mar. 20 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340524\" data-linked=\"Report: Zuckerberg, Sandberg skip Facebook employee meeting\" data-tweet=\"$FB - Report: Zuckerberg, Sandberg skip Facebook employee meeting https://seekingalpha.com/news/3340524-report-zuckerberg-sandberg-skip-facebook-employee-meeting?source=tweet\" data-url=\"https://seekingalpha.com/news/3340524-report-zuckerberg-sandberg-skip-facebook-employee-meeting\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>99&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340523\" data-ts=\"1521574263\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HL\" target=\"_blank\">HL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340523-hecla-mining-klondex-head-in-opposite-directions-following-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hecla Mining, Klondex head in opposite directions following deal</a></h4><ul>     <li>Hecla Mining (<a href='https://seekingalpha.com/symbol/HL' title='Hecla Mining Co.'>HL</a> <font color='red'>-2%</font>) extends its two-day loss to 16% in the wake of its <a href=\"https://seekingalpha.com/news/3340079-klondex-58-percent-premarket-462m-takeover-hecla-mining\" target=\"_blank\">$462M acquisition</a> of Klondex Mines (<a href='https://seekingalpha.com/symbol/KLDX' title='Klondex Mines Ltd.'>KLDX</a> <font color='green'>+0.7%</font>), as <a href=\"https://www.barrons.com/articles/the-small-cap-view-the-market-tales-from-hecla-gives-to-klondex-1521570012\" target=\"_blank\">investors seem unimpressed</a> with HL CEO Phillips Baker's promises that the deal will be &ldquo;transformational&rdquo; and create value for shareholders.</li>     <li>HL says the deal will add 162K gold equiv. oz./year of production to ~370K oz./year and would have raised last year&rsquo;s &ldquo;pro forma&rdquo; operating cash flow by $41M.</li>     <li>B. Riley FBR sees the pullback as a buying opportunity for HL, and the firm raises its price target to $5.30 from $5.</li>     <li>Meanwhile, KLDX has surged 54% in reaction to the deal despite getting downgraded to Neutral from Buy at H.C. Wainwright, which thinks the takeover may prove disappointing for shareholders in the long-term but unlocks short-term value and provides investors with upside through HL shares received.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340523\" data-linked=\"Hecla Mining, Klondex head in opposite directions following deal\" data-tweet=\"$HL $HL $KLDX - Hecla Mining, Klondex head in opposite directions following deal https://seekingalpha.com/news/3340523-hecla-mining-klondex-head-in-opposite-directions-following-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3340523-hecla-mining-klondex-head-in-opposite-directions-following-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340522\" data-ts=\"1521574075\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340522-amazons-market-cap-passes-alphabet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amazon&#39;s market cap passes Alphabet</a></h4><ul><li>        Amazon&rsquo;s (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+2.1%</font>) share gains today pushed the company&rsquo;s market cap to $764.4B, which is higher than Alphabet&rsquo;s (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-0.3%</font>) $760.93B.</li><li>                  Amazon now has the second largest market cap, but has some room to catch up on Apple&rsquo;s (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.2%</font>) $891.68B. &nbsp;&nbsp;&nbsp; </li><li>Previously: <a href=\"https://seekingalpha.com/news/3340483-goldman-sachs-amazon-hit-1900-year\" target=\"_blank\">Goldman Sachs: Amazon could hit $1,900 this year</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340522\" data-linked=\"Amazon&#39;s market cap passes Alphabet\" data-tweet=\"$AMZN $AMZN $GOOG - Amazon&#39;s market cap passes Alphabet https://seekingalpha.com/news/3340522-amazons-market-cap-passes-alphabet?source=tweet\" data-url=\"https://seekingalpha.com/news/3340522-amazons-market-cap-passes-alphabet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>153&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340520\" data-ts=\"1521573442\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LBTYA\" target=\"_blank\">LBTYA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340520-report-liberty-global-in-potential-jv-talks-switzerlands-sunrise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: Liberty Global in potential JV talks with Switzerland&#39;s Sunrise</a></h4><ul>   <li>Liberty Global (<a href=\"http://seekingalpha.com/symbol/LBTYA\" target=\"_blank\">LBTYA</a> <font color='red'>-1.5%</font>) is in talks with Sunrise Communications Group (<a href=\"http://seekingalpha.com/symbol/SNMMF\" target=\"_blank\">SNMMF</a> <font color='red'>-7.6%</font>) about the prospect of <a href=\"https://www.bloomberg.com/news/articles/2018-03-20/liberty-is-said-to-hold-talks-with-sunrise-for-swiss-partnership\" target=\"_blank\">combining their Swiss businesses</a>, Bloomberg reports.</li>    <li>That could make a combo similar to what John Malone's firm put together in the Netherlands, combining Ziggo with Vodafone's Dutch operations in a joint venture.</li>    <li>The two companies are working with advisers as they discuss a potential joint venture between Sunrise and Liberty's UPC.</li>    <li>Sunrise shares were \"partly supported by hopes/expectations&rdquo; that Liberty would pursue an all-out takeover, says Vontobel's Panagiotis Spiliopoulos. Liberty has indicated it wants to be a \"larger player\" in Switzerland.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340520\" data-linked=\"Report: Liberty Global in potential JV talks with Switzerland&#39;s Sunrise\" data-tweet=\"$LBTYA $LBTYA $SNMMF - Report: Liberty Global in potential JV talks with Switzerland&#39;s Sunrise https://seekingalpha.com/news/3340520-report-liberty-global-in-potential-jv-talks-switzerlands-sunrise?source=tweet\" data-url=\"https://seekingalpha.com/news/3340520-report-liberty-global-in-potential-jv-talks-switzerlands-sunrise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340518\" data-ts=\"1521572810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340518-credit-suisse-raises-micron-target-to-16-upside\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Credit Suisse raises its Micron target to 16% upside</a></h4><ul><li>        Credit Suisse <a href=\"https://www.cnbc.com/2018/03/20/credit-suisse-says-red-hot-chip-stock-micron-has-more-room-to-run.html\" target=\"_blank\">raises</a> its Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) price target from $60 to $70, a 16% upside to yesterday&rsquo;s close.</li><li>               The firm reiterated an Outperform rating.&nbsp;</li><li>               Analyst John Pitzer expects Q3 guidance to come in well above consensus and forecasts FY18 EPS of $10.75 (consensus: $10.36.)&nbsp;&nbsp;</li><li>               Pitzer: &ldquo;Our positive bias to Rev is driven by better memory ASPs, supported by recent contract pricing, and our positive bias to EPS driven by better cost downs, supported by an improving cost structure and better mix.&rdquo;&nbsp;</li><li>               Micron will report Q2 earnings on Thursday. &nbsp;&nbsp;</li><li>               Micron shares are&nbsp;<font color='green'>up 1.5%</font>&nbsp;to $61.04.&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3340518\" data-linked=\"Credit Suisse raises its Micron target to 16% upside\" data-tweet=\"$MU - Credit Suisse raises its Micron target to 16% upside https://seekingalpha.com/news/3340518-credit-suisse-raises-micron-target-to-16-upside?source=tweet\" data-url=\"https://seekingalpha.com/news/3340518-credit-suisse-raises-micron-target-to-16-upside\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>133&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340515\" data-ts=\"1521572168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MULE\" target=\"_blank\">MULE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340515-technology-top-gainers-losers-of-2_55-pm-3-20-18\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2.55 pm (3/20/18)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+13%</font>.<a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/ZS' title='Zscaler'>ZS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BAND' title='Bandwidth, Inc.'>BAND</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-26%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340515\" data-linked=\"Technology - Top Gainers / Losers as of 2.55 pm (3/20/18)\" data-tweet=\"$MULE $MULE $VSLR - Technology - Top Gainers / Losers as of 2.55 pm (3/20/18) https://seekingalpha.com/news/3340515-technology-top-gainers-losers-of-2_55-pm-3-20-18?source=tweet\" data-url=\"https://seekingalpha.com/news/3340515-technology-top-gainers-losers-of-2_55-pm-3-20-18\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:56 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340513\" data-ts=\"1521571889\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNI\" target=\"_blank\">MNI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340513-mcclatchy-adds-boeings-farr-chief-accounting-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McClatchy adds Boeing&#39;s Farr as chief accounting officer</a></h4><ul>   <li>McClatchy (<a href=\"http://seekingalpha.com/symbol/MNI\" target=\"_blank\">MNI</a> <font color='red'>-3.6%</font>) has made Peter Farr its new <a href=\"https://finance.yahoo.com/news/mcclatchy-names-peter-farr-controller-130000984.html\" target=\"_blank\">chief accounting officer</a> and controller.</li>    <li>The hire is effective April 16; Farr is currently Northwest accounting policy director for Boeing.</li>    <li>He has prior experience in industry and with Deloitte &amp; Touche. \"He will be a great addition to our team as we continue our digital transformation and expand our digital products and services,\" says CFO Elaine Lintecum.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340513\" data-linked=\"McClatchy adds Boeing&#39;s Farr as chief accounting officer\" data-tweet=\"$MNI - McClatchy adds Boeing&#39;s Farr as chief accounting officer https://seekingalpha.com/news/3340513-mcclatchy-adds-boeings-farr-chief-accounting-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3340513-mcclatchy-adds-boeings-farr-chief-accounting-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:51 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340511\" data-ts=\"1521571005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRI\" target=\"_blank\">NTRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340511-nutrisystemminus-2_5-argus-warns-on-growth-prospects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NutriSystem -2.5% as Argus warns on growth prospects</a></h4><ul>   <li>NutriSystem (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a>) is <font color='red'>off 2.5%</font> after a <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11389169/nutrisystem-hit-with-downgrade-on-weaker-near-term-grow\" target=\"_blank\">downgrade to Hold</a> at Argus, which sees weaker prospects for growth ahead.</li>    <li>The firm cut its 2018 EPS estimate to $2.02 from $2.16 (vs. consensus of $2.03), and set its 2019 estimate to $2.40 (slightly above consensus for $2.36).</li>    <li>A sales and marketing revamp is ahead, analyst John Staszak says, and \"given the company's weaker near-term growth prospects, we believe that NTRI shares are fairly valued at 15.5-times our revised 2018 EPS estimate, toward the low end of the three-year historical range of 13-34.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340511\" data-linked=\"NutriSystem -2.5% as Argus warns on growth prospects\" data-tweet=\"$NTRI - NutriSystem -2.5% as Argus warns on growth prospects https://seekingalpha.com/news/3340511-nutrisystemminus-2_5-argus-warns-on-growth-prospects?source=tweet\" data-url=\"https://seekingalpha.com/news/3340511-nutrisystemminus-2_5-argus-warns-on-growth-prospects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340510\" data-ts=\"1521570989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANCUF\" target=\"_blank\">ANCUF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340510-couche-tard-falls-in-two-years-on-slow-u-s-store-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Couche-Tard falls most in two years on slow U.S. store sales</a></h4><ul><li>Shares of Circle K owner Alimentation Couche-Tard (<a href='https://seekingalpha.com/symbol/ANCUF' title='Alimentation Couche-Tard Inc.'>OTCPK:ANCUF</a> <font color='red'>-6.6%</font>) <a href=\"http://business.financialpost.com/investing/market-moves/couche-tard-shares-plunge-the-most-in-two-years-after-u-s-store-sales-slow\" target=\"_blank\">plunge by the most in two years</a> after the company reports much worse than expected <a href=\"https://seekingalpha.com/news/3340404-alimentation-couche-tard-misses-0_22-beats-revenue\" target=\"_blank\">Q4 earnings</a> and weak same-store sales.</li><li>The company says Q4 same-store merchandise revenue rose just 0.1% in the U.S., its biggest  market, compared with a 1.9% increase in the year-ago quarter, and same-store road  transportation fuel volume fell 0.4%, with fuel  margins dropping $0.026/gal.</li><li>Couche-Tard says same-store sales at CST, the gas station company it bought for nearly $4B last year, fell 1% but are  improving; also, fuel volumes decreased in Texas as stores recovered  from Hurricane Harvey.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340510\" data-linked=\"Couche-Tard falls most in two years on slow U.S. store sales\" data-tweet=\"$ANCUF - Couche-Tard falls most in two years on slow U.S. store sales https://seekingalpha.com/news/3340510-couche-tard-falls-in-two-years-on-slow-u-s-store-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3340510-couche-tard-falls-in-two-years-on-slow-u-s-store-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340506\" data-ts=\"1521568965\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INXN\" target=\"_blank\">INXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340506-interxion-in-new-225m-revolving-credit-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InterXion in new \u20ac225M revolving credit deal</a></h4><ul>   <li>InterXion (<a href=\"http://seekingalpha.com/symbol/INXN\" target=\"_blank\">INXN</a> <font color='green'>+1.7%</font>) has entered an agreement for a new &euro;225M <a href=\"https://seekingalpha.com/filing/3943988\" target=\"_blank\">revolving credit facility</a>.</li>    <li>The unsecured subordinated revolver was entered into with ABN AMRO and BofA Merrill Lynch International, and it has an initial maturity of Dec. 31, 2018, with the option to extend to Dec. 31, 2019.</li>    <li>It bears initial interest of Euribor plus a margin of 3% annually, with a Euribor floor of 0%, subject to a potential ratchet (but a maximum margin of 4.5%/year).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340506\" data-linked=\"InterXion in new \u20ac225M revolving credit deal\" data-tweet=\"$INXN - InterXion in new \u20ac225M revolving credit deal https://seekingalpha.com/news/3340506-interxion-in-new-225m-revolving-credit-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3340506-interxion-in-new-225m-revolving-credit-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340497\" data-ts=\"1521564740\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GPI\" target=\"_blank\">GPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340497-group-1-automotiveminus-9-after-warning-on-q1-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Group 1 Automotive -9% after warning on Q1 earnings</a></h4><ul>     <li>Group 1 Automotive (<a href='https://seekingalpha.com/symbol/GPI' title='Group 1 Automotive Inc.'>GPI</a> <font color='red'>-9.2%</font>) plunges after warning that <a href=\"https://seekingalpha.com/pr/17106043-group-1-announces-market-conditions-costs-associated-strategic-initiatives-will-negatively\" target=\"_blank\">Q1 earnings will be hurt</a> by weak market conditions, including pressure on used car margins.</li>     <li>GPI also cites an anticipated $3M in costs during Q1 and Q2 associated with a series of long-term investments designed to strengthen the used vehicle, parts and service components of its  business, including the introduction of Val-U-Line, a brand for high mileage  pre-owned vehicles, and investments in aftersales and retention  programs for dealership employees.</li>     <li>\"The recent peak in the new vehicle market in both the U.S. and U.K. and the flood of nearly-new and off-lease used vehicles into these markets are applying significant pressure to our margins, which require that we seek additional used car and service volume [through] some significant upfront investments to support our long-term strategies,\"&nbsp;GPI says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340497\" data-linked=\"Group 1 Automotive -9% after warning on Q1 earnings\" data-tweet=\"$GPI - Group 1 Automotive -9% after warning on Q1 earnings https://seekingalpha.com/news/3340497-group-1-automotiveminus-9-after-warning-on-q1-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3340497-group-1-automotiveminus-9-after-warning-on-q1-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340496\" data-ts=\"1521564337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOAH\" target=\"_blank\">NOAH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340496-financials-top-5-gainers-losers-of-12-45-pm-03-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 12:45 PM (03/20/2018)</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/SACH' title='Sachem Capital'>SACH</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/KINS' title='Kingstone Companies Inc'>KINS</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LEJU' title='Leju Holdings Limited'>LEJU</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/FRSX' title='Foresight Autonomous Holdings Ltd.'>FRSX</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340496\" data-linked=\"Financials - Top 5 Gainers / Losers as of 12:45 PM (03/20/2018)\" data-tweet=\"$NOAH $NOAH $SACH - Financials - Top 5 Gainers / Losers as of 12:45 PM (03/20/2018) https://seekingalpha.com/news/3340496-financials-top-5-gainers-losers-of-12-45-pm-03-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340496-financials-top-5-gainers-losers-of-12-45-pm-03-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340494\" data-ts=\"1521564320\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340494-midday-gainers-losers-03-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers (03/20/2018)</a></h4><ul><li><a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+33%</font>. CRME <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SRI' title='Stoneridge, Inc.'>SRI</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/ACMR' title='ACM Research, Inc.'>ACMR</a> <font color='green'>+15%</font>.  <a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+15%</font>.<a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+14%</font>.<a href='https://seekingalpha.com/symbol/PAR' title='PAR Technology Corporation'>PAR</a> <font color='green'>+14%</font>.<a href='https://seekingalpha.com/symbol/VSLR' title='Vivint Solar'>VSLR</a> <font color='green'>+13%</font>.<a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a> <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a>&nbsp;<font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a>&nbsp;<font color='red'>-20%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>&nbsp;<font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a>&nbsp;<font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a>&nbsp;<font color='red'>-17%</font>.  <a href='https://seekingalpha.com/symbol/WMLP-OLD' title='Westmoreland Resource Partners, LP'>WMLP-OLD</a>&nbsp;<font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/OPNT' title='Opiant Pharmaceuticals, Inc.'>OPNT</a>&nbsp;<font color='red'>-15%</font>.<a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a>&nbsp;<font color='red'>-14%</font>.<a href='https://seekingalpha.com/symbol/DPW' title='DPW Holdings, Inc.'>DPW</a>&nbsp;<font color='red'>-14%</font>.<a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a>&nbsp;<font color='red'>-13%</font>.<a href='https://seekingalpha.com/symbol/HQY' title='HealthEquity'>HQY</a>&nbsp;<font color='red'>-12%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340494\" data-linked=\"Midday Gainers / Losers (03/20/2018)\" data-tweet=\"$ARNA $ARNA $CORV - Midday Gainers / Losers (03/20/2018) https://seekingalpha.com/news/3340494-midday-gainers-losers-03-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340494-midday-gainers-losers-03-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340492\" data-ts=\"1521563615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMG\" target=\"_blank\">CMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340492-chipotle-taps-former-bloomin-brands-exec-brandt-chief-marketing-officer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chipotle taps former Bloomin&#39; Brands exec Brandt as chief marketing officer</a></h4><ul>     <li>Chipotle Mexican Grill (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+1.8%</font>) names Chris Brandt as its <a href=\"https://seekingalpha.com/pr/17107298-chipotle-names-chris-brandt-chief-marketing-officer\" target=\"_blank\">new chief marketing officer</a>, effective April 2, succeeding Mark Crumpacker, who resigned <a href=\"https://seekingalpha.com/news/3339156-chipotle-marketing-boss-steps\" target=\"_blank\">last week</a>.</li>     <li>Brandt comes from Bloomin' Brands (<a href='https://seekingalpha.com/symbol/BLMN' title='Bloomin&#39; Brands'>BLMN</a> <font color='green'>+2.4%</font>), where he was executive VP and chief brand officer across Outback Steakhouse, Carrabba's, Bonefish Grill and Fleming's, after previously serving as chief brand and marketing officer at YUM! Brands' Taco Bell.</li>     <li>\"Having worked with Chris in the past, I have seen first-hand his ability to generate sales overnight and build brands over time,\" says CMG&nbsp;CEO Brian Niccol.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340492\" data-linked=\"Chipotle taps former Bloomin&#39; Brands exec Brandt as chief marketing officer\" data-tweet=\"$CMG $CMG $BLMN - Chipotle taps former Bloomin&#39; Brands exec Brandt as chief marketing officer https://seekingalpha.com/news/3340492-chipotle-taps-former-bloomin-brands-exec-brandt-chief-marketing-officer?source=tweet\" data-url=\"https://seekingalpha.com/news/3340492-chipotle-taps-former-bloomin-brands-exec-brandt-chief-marketing-officer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:33 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340486\" data-ts=\"1521561726\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340486-stifel-downgrades-oracle-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel downgrades Oracle after earnings</a></h4><ul><li>        Stifel <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11388576/stifel-projects-a-prolonged-state-of-transition-for-ora\" target=\"_blank\">downgrades</a> Oracle (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) from Buy to Hold with a $53 price target after yesterday&rsquo;s earnings report.</li><li>               Analyst Brad Reback cites SaaS revenue missing estimates with &ldquo;legacy&rdquo; acquired SaaS properties only growing at a low single-digit rate.&nbsp;</li><li>               Reback calls the earnings report &ldquo;lackluster&rdquo; and the outlook concerning, saying the company will likely stay in a &ldquo;state of transition in coming years.&rdquo; &nbsp;&nbsp;</li><li>               Oracle shares are&nbsp;<font color='red'>down 10.1%</font>&nbsp;to $46.73.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340281-oracle-minus-2_6-percent-q3-line-revenue-32-percent-cloud-revenue-growth\" target=\"_blank\">Oracle -2.6% on Q3 in-line revenue, 32% cloud revenue growth</a> (March 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340374-oracle-q4-guidance-features-cloud-disappointment\" target=\"_blank\">Oracle Q4 guidance features cloud disappointment</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340486\" data-linked=\"Stifel downgrades Oracle after earnings\" data-tweet=\"$ORCL - Stifel downgrades Oracle after earnings https://seekingalpha.com/news/3340486-stifel-downgrades-oracle-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3340486-stifel-downgrades-oracle-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340484\" data-ts=\"1521561388\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340484-facebook-and-social-peers-keep-sinking-on-spiraling-regulatory-news-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook and social peers keep sinking on spiraling regulatory news (updated)</a></h4><ul>   <li>With regulatory pressure on Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) seemingly ramping up by the minute, peer companies' stocks are feeling the heat as well.</li>    <li>Shares in the social-networking giant are now <font color='red'>off 5.8%</font>, trimming more billions from its market cap. Despite broader market gains, Twitter (NYSE:<a href='https://seekingalpha.com/symbol/TWTR' title='Twitter, Inc.'>TWTR</a>) is <font color='red'>9.7% lower</font> today; Alphabet is lower as well (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-1.3%</font>, <a href='https://seekingalpha.com/symbol/GOOGL' title='Alphabet, Inc. Cl A'>GOOGL</a> <font color='red'>-1.5%</font>); and Snap (NYSE:<a href='https://seekingalpha.com/symbol/SNAP' title='Snap Inc.'>SNAP</a>) is <font color='red'>down 4.3%</font>.</li>    <li>Facebook now faces the <a href=\"https://seekingalpha.com/news/3340437-facebook-minus-2_7-percent-report-ftc-investigating-data-issue\" target=\"_blank\">prospect of an FTC inquiry</a>, and has gotten a request to appear before Parliament in the UK.</li>    <li>Facebook's deputy chief privacy officer says \"We appreciate the opportunity to answer questions the FTC may have.\"</li>    <li>The company's officials have tentatively agreed to brief House Judiciary members as soon as tomorrow on the Cambridge Analytica situation, Bloomberg reporters are saying. Senate Judiciary Chairman Charles Grassley is considering his own hearing to bring in CEOs from Facebook, Twitter and Google.</li><li>Speculation is growing that all the peer companies could be hauled before multiple government committees to answer for data practices.</li><li><strong>Updated 1:15 p.m.:</strong> Add the House Energy &amp; Commerce Committee and the Senate Commerce Committee to those getting Facebook briefings.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340484\" data-linked=\"Facebook and social peers keep sinking on spiraling regulatory news (updated)\" data-tweet=\"$FB $FB $TWTR - Facebook and social peers keep sinking on spiraling regulatory news (updated) https://seekingalpha.com/news/3340484-facebook-and-social-peers-keep-sinking-on-spiraling-regulatory-news-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3340484-facebook-and-social-peers-keep-sinking-on-spiraling-regulatory-news-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>150&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340483\" data-ts=\"1521561095\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340483-goldman-sachs-amazon-hit-1900-this-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Goldman Sachs: Amazon could hit $1,900 this year</a></h4>&nbsp; <ul><li>        Goldman Sachs <a href=\"https://www.cnbc.com/2018/03/20/amazon-shares-could-easily-hit-1900-in-2018-goldman-sachs.html\" target=\"_blank\">says</a> Amazon (NASDAQ:<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a>) shares could &ldquo;easily&rdquo; hit up to $1,900 this year, which is $75 higher than the firm&rsquo;s last price target for the tech giant.</li><li>               The higher target would represent a 23% upside to yesterday&rsquo;s close.&nbsp;</li><li>               Analyst Heath Terry tells CNBC that Amazon still has the potential for upsides particularly from Amazon Web Services and a continuing shift towards online retail sales.&nbsp;</li><li>               Terry says the firm continues to think estimates for cloud and retail are too low.&nbsp;</li><li>               Amazon shares are&nbsp;<font color='green'>up 1.3%</font>&nbsp;to $1,565.12.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340386-reuters-amazon-pushing-merchants-cross-border-sales\" target=\"_blank\">Reuters: Amazon pushing merchants for cross-border sales</a> (March 20)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340483\" data-linked=\"Goldman Sachs: Amazon could hit $1,900 this year\" data-tweet=\"$AMZN - Goldman Sachs: Amazon could hit $1,900 this year https://seekingalpha.com/news/3340483-goldman-sachs-amazon-hit-1900-this-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3340483-goldman-sachs-amazon-hit-1900-this-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340479\" data-ts=\"1521560556\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MULE\" target=\"_blank\">MULE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340479-mulesoftplus-22_4-on-acquisition-target-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MuleSoft +22.4% on acquisition target news</a></h4><ul><li>        MuleSoft (NYSE:<a href='https://seekingalpha.com/symbol/MULE' title='MuleSoft'>MULE</a>) shares&nbsp;<font color='green'>soar 22.4%</font>&nbsp;after a <a href=\"https://www.reuters.com/article/us-mulesoft-m-a-salesforce-exclusive/exclusive-salesforce-in-advanced-talks-to-buy-mulesoft-sources-idUSKBN1GW24N\" target=\"_blank\">Reuters report</a> that Salesforce (<a href='https://seekingalpha.com/symbol/CRM' title='Salesforce.com, Inc.'>CRM</a> <font color='green'>+0.7%</font>) is in advanced discussions to acquire the company.&nbsp;</li><li>        Reuters&rsquo; source says the deal announcement could come as soon as this week but warns that the negotiations aren&rsquo;t finalized, and the deal could fall through or change.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3340479\" data-linked=\"MuleSoft +22.4% on acquisition target news\" data-tweet=\"$MULE $MULE $CRM - MuleSoft +22.4% on acquisition target news https://seekingalpha.com/news/3340479-mulesoftplus-22_4-on-acquisition-target-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3340479-mulesoftplus-22_4-on-acquisition-target-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:42 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340472\" data-ts=\"1521559717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIG\" target=\"_blank\">SIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340472-signet-jewelersminus-2_4-bofa-goes-to-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Signet Jewelers -2.4% as BofA goes to Neutral</a></h4><ul>   <li>Signet Jewelers (NYSE:<a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a>) is <font color='red'>down 2.4%</font> after a cut to Neutral at BofA Merrill Lynch, which sees \"no visibility\" on when comps will turn at the retailer.</li>    <li>The firm cut its price target to $43 from $66, implying 11.7% upside from today's depressed price.</li>    <li>The current price looks cheap on a P/E basis, but not on other multiples like enterprise value to EBITDA, the firm says.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3340472\" data-linked=\"Signet Jewelers -2.4% as BofA goes to Neutral\" data-tweet=\"$SIG - Signet Jewelers -2.4% as BofA goes to Neutral https://seekingalpha.com/news/3340472-signet-jewelersminus-2_4-bofa-goes-to-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3340472-signet-jewelersminus-2_4-bofa-goes-to-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340471\" data-ts=\"1521559703\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOV\" target=\"_blank\">DOV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340471-dover-president-ceo-livingston-to-retire-tobin-to-take-charge\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dover President/CEO Livingston to retire; Tobin to take charge</a></h4><ul>     <li>Dover (<a href='https://seekingalpha.com/symbol/DOV' title='Dover Corp'>DOV</a> <font color='green'>+4%</font>) says President and CEO Robert Livingston <a href=\"https://www.sec.gov/Archives/edgar/data/29905/000119312518088722/d537879dex991.htm\" target=\"_blank\">will retire</a> effective April 30 after a 35-year career with the company, to be succeeded by former CNH&nbsp;Industrial (<a href='https://seekingalpha.com/symbol/CNHI' title='CNH Industrial N.V.'>CNHI</a> <font color='red'>-1.4%</font>) CEO Richard Tobin.</li>     <li>Tobin, a member of DOV's board since 2016, was CNH Industrial's CEO during 2013-18 after serving as Group COO of Fiat Industrial</li>     <li>CNH said yesterday that Tobin was resigning, with company executive Derek Neilson taking over on an interim basis.</li>     <li>Livingston has been DOV's President and CEO since 2008 after joining the company in 1983.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340471\" data-linked=\"Dover President/CEO Livingston to retire; Tobin to take charge\" data-tweet=\"$DOV $DOV $CNHI - Dover President/CEO Livingston to retire; Tobin to take charge https://seekingalpha.com/news/3340471-dover-president-ceo-livingston-to-retire-tobin-to-take-charge?source=tweet\" data-url=\"https://seekingalpha.com/news/3340471-dover-president-ceo-livingston-to-retire-tobin-to-take-charge\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340468\" data-ts=\"1521559194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MDWD\" target=\"_blank\">MDWD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340468-mediwound-continues-rally-up-17\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MediWound continues rally, up 17%</a></h4><ul><li>Thinly traded micro cap MediWound (<a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='green'>+16.6%</font>) is up on a 4x surge in volume, albeit on turnover of only 139K shares. The stock has rallied almost 40% since last Thursday.</li><li>In the company's <a href=\"https://seekingalpha.com/pr/17105168-mediwound-reports-fourth-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">Q4 earnings release</a> yesterday, it announced that it has been approached by another company about a strategic transaction. The board has engaged Moelis &amp; Co. to advise.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340468\" data-linked=\"MediWound continues rally, up 17%\" data-tweet=\"$MDWD - MediWound continues rally, up 17% https://seekingalpha.com/news/3340468-mediwound-continues-rally-up-17?source=tweet\" data-url=\"https://seekingalpha.com/news/3340468-mediwound-continues-rally-up-17\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340438\" data-ts=\"1521558936\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340438-healthcare-top-5-gainers-losers-of-11-15-3-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:15 am (3/20/2018)</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+33%</font>. <a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+24%</font>.CRME <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/MDWD' title='Mediwound Ltd.'>MDWD</a> <font color='green'>+17%</font>. <a href='https://seekingalpha.com/symbol/VERU' title='Veru Inc.'>VERU</a> <font color='green'>+13%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/DRNA' title='Dicerna Pharmaceuticals, Inc.'>DRNA</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/ENDP' title='Endo International plc'>ENDP</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a> <font color='red'>-10%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340438\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:15 am (3/20/2018)\" data-tweet=\"$ARNA $ARNA $MRNS - Healthcare - Top 5 Gainers / Losers as of 11:15 am (3/20/2018) https://seekingalpha.com/news/3340438-healthcare-top-5-gainers-losers-of-11-15-3-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340438-healthcare-top-5-gainers-losers-of-11-15-3-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340466\" data-ts=\"1521558639\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATBPF\" target=\"_blank\">ATBPF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340466-antibes-atbminus-346-successful-in-mid-stage-gi-safety-study-shares-up-71\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Antibe&#39;s ATB-346 successful in mid-stage GI safety study; shares up 71%</a></h4><ul><li>Thinly traded micro cap Antibe Therapeutics (<a href='https://seekingalpha.com/symbol/ATBPF' title='Antibe Therapeutics, Inc.'>OTCQB:ATBPF</a> <font color='green'>+71%</font>) is up on over a 6x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/17106757-antibe-therapeutics-announces-successful-phase-2b-gastrointestinal-safety-study-lead-pain\" target=\"_blank\">announcement </a>of positive results from a Phase 2b gastrointestinal &#40;GI&#41; study of lead drug ATB-346.</li><li>The data showed the superiority of ATB-346 compared to naproxen as determined by the ulceration rate at the end of a two-week treatment period. Specifically, the ulceration rate in the ATB-346 cohort was 2.5% versus 42.1% for naproxen (p&lt;0.001).</li><li>Detailed results will be released next quarter. Data from a dose-ranging and effectiveness study should be available in Q4.</li><li>The company is seeking development and commercialization partners for the major markets.</li><li><a href=\"http://www.antibethera.com/pipeline/atb-346/\" target=\"_blank\">ATB-346</a>&nbsp;is a derivative of naproxen, the most commonly prescribed NSAID. Its value proposition is naproxen-equivalent anti-inflammatory action without the gastrointestinal ulceration.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3338749-antibe-continues-move-ahead-key-data-readout-shares-ahead-3-percent\" target=\"_blank\">Antibe continues up move ahead of key data readout, shares ahead 3%</a> (March 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340466\" data-linked=\"Antibe&#39;s ATB-346 successful in mid-stage GI safety study; shares up 71%\" data-tweet=\"$ATBPF - Antibe&#39;s ATB-346 successful in mid-stage GI safety study; shares up 71% https://seekingalpha.com/news/3340466-antibes-atbminus-346-successful-in-mid-stage-gi-safety-study-shares-up-71?source=tweet\" data-url=\"https://seekingalpha.com/news/3340466-antibes-atbminus-346-successful-in-mid-stage-gi-safety-study-shares-up-71\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340463\" data-ts=\"1521558199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CACI\" target=\"_blank\">CACI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340463-caci-internationalplus-3_1-raymond-james-goes-to-strong-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CACI International +3.1% as Raymond James goes to Strong Buy</a></h4><ul>   <li>CACI International (NYSE:<a href='https://seekingalpha.com/symbol/CACI' title='CACI International Inc'>CACI</a>) is <font color='green'>up 3.1%</font> as Raymond James likes the company's upside even if it loses out on its bid for CSRA.</li>    <li>That's the likely outcome, analyst Brian Gesuale says, with General Dynamics raising its CSRA bid to $41.25 in cash.</li>    <li>But a bidding war with GD can only be negative in the near term, he continues, and there's a 90% chance of a positive outcome for CACI regardless of the CSRA bid.</li>    <li>He's upgraded CACI to Strong Buy from Outperform, and raised his price target to $175 from $159, implying 17% upside from today's higher price.</li>    <li>Meanwhile, Loop Capital has raised its price target to $172.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340432-general-dynamics-ups-csra-offer-41_25-share\" target=\"_blank\">General Dynamics ups CSRA offer to $41.25/share</a> (Mar. 20 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340463\" data-linked=\"CACI International +3.1% as Raymond James goes to Strong Buy\" data-tweet=\"$CACI - CACI International +3.1% as Raymond James goes to Strong Buy https://seekingalpha.com/news/3340463-caci-internationalplus-3_1-raymond-james-goes-to-strong-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3340463-caci-internationalplus-3_1-raymond-james-goes-to-strong-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340460\" data-ts=\"1521557668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340460-bofaml-survey-tech-longs-38-overweight-last-month\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML survey: Tech longs 38% overweight last month</a></h4><ul><li>        Bank of America Merrill Lynch&rsquo;s <a href=\"https://www.reuters.com/article/us-funds-baml-survey/investors-crowded-into-tech-sector-baml-march-survey-finds-idUSKBN1GW1UJ?feedType=RSS&amp;feedName=technologyNews&amp;utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+reuters%2FtechnologyNews+%28Reuters+Technology+News%29\" target=\"_blank\">latest monthly survey</a> shows that investors were heavily exposed to tech shares.</li><li>               Long investors in the tech sector were the No. 1 crowded trade with a net 38% overweight. Short dollar positions were 17% overweight.&nbsp;</li><li>               Top investments were in the FAANG stocks (<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a> <font color='red'>-2.8%</font>), (<a href='https://seekingalpha.com/symbol/AMZN' title='Amazon.com, Inc.'>AMZN</a> <font color='green'>+1.6%</font>), Apple (<a href='https://seekingalpha.com/symbol/AAPL' title='Apple Inc.'>AAPL</a> <font color='green'>+0.5%</font>), Netflix (<a href='https://seekingalpha.com/symbol/NFLX' title='Netflix, Inc.'>NFLX</a> <font color='green'>+1.7%</font>), and Alphabet (<a href='https://seekingalpha.com/symbol/GOOG' title='Alphabet, Inc. Cl C'>GOOG</a> <font color='red'>-0.1%</font>) and the BAT stocks, which includes Baidoo, Alibaba (<a href='https://seekingalpha.com/symbol/BABA' title='Alibaba Group Holding Limited'>BABA</a> <font color='green'>+1.9%</font>), and Tencent (<a href='https://seekingalpha.com/symbol/TCEHY' title='Tencent Holding Ltd. ADR'>OTCPK:TCEHY</a> <font color='green'>+2.4%</font>).&nbsp;</li><li>               The survey included fund managers running $579B worldwide and was conducted from March 9 to March 15.&nbsp;&nbsp;</li><li>Related ETFs: <a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>, <a href='https://seekingalpha.com/symbol/VGT' title='Vanguard Information Technology ETF'>VGT</a>, <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/FDN' title='First Trust DJ Internet Index ETF'>FDN</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/GGT' title='Gabelli Global Multimedia Trust'>GGT</a>, <a href='https://seekingalpha.com/symbol/TECL' title='Direxion Technology Bull 3x Shares ETF'>TECL</a>, <a href='https://seekingalpha.com/symbol/FTEC' title='Fidelity MSCI Information Technology Index ETF'>FTEC</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/VOX' title='Vanguard Telecom Services ETF'>VOX</a>, <a href='https://seekingalpha.com/symbol/IYW' title='iShares U.S. Technology ETF'>IYW</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/TDIV' title='First Trust NASDAQ Technology Dividend Index ETF'>TDIV</a>, <a href='https://seekingalpha.com/symbol/ROM' title='ProShares Ultra Technology ETF'>ROM</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/QTEC' title='First Trust NASDAQ-100-Tech Index ETF'>QTEC</a>, <a href='https://seekingalpha.com/symbol/IYZ' title='iShares U.S. Telecommunications ETF'>IYZ</a>, <a href='https://seekingalpha.com/symbol/IGV' title='iShares Expanded Tech-Software Sector ETF'>IGV</a>, <a href='https://seekingalpha.com/symbol/RYT' title='Invesco S&P 500 Equal Weight Technology ETF'>RYT</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/FNG' title='AdvisorShares New Tech and Media ETF'>FNG</a>, <a href='https://seekingalpha.com/symbol/TECS' title='Direxion Technology Bear 3x Shares ETF'>TECS</a>, <a href='https://seekingalpha.com/symbol/IGM' title='iShares North American Tech ETF'>IGM</a>, <a href='https://seekingalpha.com/symbol/PSCT' title='Invesco S&P SmallCap Information Technology Portfolio ETF'>PSCT</a>, <a href='https://seekingalpha.com/symbol/FCOM' title='Fidelity MSCI Telecommunications Services Index ETF'>FCOM</a>, <a href='https://seekingalpha.com/symbol/FXL' title='First Trust Tech AlphaDEX ETF'>FXL</a>, <a href='https://seekingalpha.com/symbol/PBS' title='Invesco Dynamic Media Portfolio ETF'>PBS</a>, <a href='https://seekingalpha.com/symbol/XNTK' title='SPDR NYSE Technology ETF'>XNTK</a>, <a href='https://seekingalpha.com/symbol/XTL' title='SPDR S&P Telecom ETF'>XTL</a>, <a href='https://seekingalpha.com/symbol/REW' title='ProShares UltraShort Technology ETF'>REW</a>, <a href='https://seekingalpha.com/symbol/IGN' title='iShares North American Tech-Multimedia Networking ETF'>IGN</a>, <a href='https://seekingalpha.com/symbol/PSJ' title='Invesco Dynamic Software Portfolio ETF'>PSJ</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/PTF' title='Invesco DWA Technology Momentum Portfolio ETF'>PTF</a>, <a href='https://seekingalpha.com/symbol/PXQ' title='Invesco Dynamic Networking Portfolio ETF'>PXQ</a>, <a href='https://seekingalpha.com/symbol/XSW' title='SPDR Software & Services ETF'>XSW</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/LTL' title='ProShares Ultra Telecommunications ETF'>LTL</a>, <a href='https://seekingalpha.com/symbol/JHMT' title='John Hancock Multifactor Technology ETF'>JHMT</a>, <a href='https://seekingalpha.com/symbol/XWEB' title='SPDR S&P Internet ETF'>XWEB</a>, <a href='https://seekingalpha.com/symbol/XITK' title='SPDR Innovative Technology ETF'>XITK</a>, <a href='https://seekingalpha.com/symbol/TCHF' title='iShares Edge MSCI Multifactor Technology ETF'>TCHF</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a>, <a href='https://seekingalpha.com/symbol/TECZ' title='Direxion Daily Technology Bear 1x Shares ETF'>TECZ</a>, <a href='https://seekingalpha.com/symbol/XK' title='Elkhorn S&P MidCap Information Technology ETF'>XK</a>, <a href='https://seekingalpha.com/symbol/FNGD' title='BMO REX MicroSectors FANG+ Index -3X Inverse Leveraged ETN'>FNGD</a>, <a href='https://seekingalpha.com/symbol/FNGU' title='BMO REX MicroSector FANG+ Index 3X Leveraged ETN'>FNGU</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3340460\" data-linked=\"BofAML survey: Tech longs 38% overweight last month\" data-tweet=\"$FB $FB $AMZN - BofAML survey: Tech longs 38% overweight last month https://seekingalpha.com/news/3340460-bofaml-survey-tech-longs-38-overweight-last-month?source=tweet\" data-url=\"https://seekingalpha.com/news/3340460-bofaml-survey-tech-longs-38-overweight-last-month\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340455\" data-ts=\"1521557103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CASI\" target=\"_blank\">CASI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340455-casi-pharma-secures-50m-private-capital-raise-ahead-of-china-debut-shares-up-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CASI Pharma secures $50M private capital raise ahead of China debut; shares up 10%</a></h4><ul><li>Thinly traded micro cap CASI Pharmaceuticals (<a href='https://seekingalpha.com/symbol/CASI' title='CASI Pharmaceuticals'>CASI</a> <font color='green'>+10.3%</font>) is up on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17107061-casi-pharmaceuticals-announces-50-million-private-placement-prepare-company-commercialization\" target=\"_blank\">announcement </a>of a $50M private placement of stock and warrants that will fund the launch of its first commercial product in China.</li><li>Specifically, the company has agreed to sell ~15.4M shares of common stock and five-year warrants to purchase an aggregate of ~6.2M shares of common at a combined price of $3.24. The warrants are exercisable at $3.69 per common share.</li><li>Closing date is March 21.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340455\" data-linked=\"CASI Pharma secures $50M private capital raise ahead of China debut; shares up 10%\" data-tweet=\"$CASI - CASI Pharma secures $50M private capital raise ahead of China debut; shares up 10% https://seekingalpha.com/news/3340455-casi-pharma-secures-50m-private-capital-raise-ahead-of-china-debut-shares-up-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3340455-casi-pharma-secures-50m-private-capital-raise-ahead-of-china-debut-shares-up-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340453\" data-ts=\"1521556644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTI\" target=\"_blank\">PTI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340453-kerrisdale-bearish-on-proteostasis-shares-down-16\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kerrisdale bearish on Proteostasis; shares down 16%</a></h4><ul><li>Proteostasis Therapeutics (<a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-16.3%</font>) is down on double normal volume in apparent reaction to a <a href=\"https://www.kerrisdalecap.com/wp-content/uploads/2018/03/Proteostasis-Therapeutics-Inc.-PTI.pdf\" target=\"_blank\">bearish report</a> from institutional investor Kerrisdale Capital who sees a 70 - 90% downside in price based on the lack of efficacy of CF candidate PTI-428.</li><li>Kerrisdale says the Phase 2 results announced in December that appeared to demonstrate PTI-428's treatment effect versus placebo is a chimera since the separation was due to the poor performance of the placebo cohort and not the treatment group. It also cites whether the targeted biomarkers can be reliably measured and the company's sequestering of negative/marginal trial data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3317684-proteostasis-advances-cystic-fibrosis-pipeline-shares-ahead-59-percent-premarket\" target=\"_blank\">Proteostasis advances cystic fibrosis pipeline; shares ahead 59% premarket</a> (Dec. 12, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340453\" data-linked=\"Kerrisdale bearish on Proteostasis; shares down 16%\" data-tweet=\"$PTI - Kerrisdale bearish on Proteostasis; shares down 16% https://seekingalpha.com/news/3340453-kerrisdale-bearish-on-proteostasis-shares-down-16?source=tweet\" data-url=\"https://seekingalpha.com/news/3340453-kerrisdale-bearish-on-proteostasis-shares-down-16\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340450\" data-ts=\"1521556219\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QRVO\" target=\"_blank\">QRVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340450-qorvominus-2_9-nomura-cuts-to-neutral-on-iphone-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qorvo -2.9% as Nomura cuts to Neutral on iPhone share</a></h4><ul>   <li>Qorvo (NASDAQ:<a href='https://seekingalpha.com/symbol/QRVO' title='Qorvo, Inc'>QRVO</a>) is <font color='red'>2.9% lower</font> today after Nomura has downgraded to Neutral on concerns the firm may have less share in the new iPhone than previously expected.</li>    <li>That's a key mover with Apple making up almost half Qorvo's revenue.</li>    <li>Based on its research, Nomura had thought Qorvo had won 100% of the mid/high-band PAD socket in the phone, but new checks suggest Broadcom may have a majority of the socket.</li>    <li>Nomura trimmed its price target to $75 from $85, implying 1.5% downside from today's lower price.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340450\" data-linked=\"Qorvo -2.9% as Nomura cuts to Neutral on iPhone share\" data-tweet=\"$QRVO - Qorvo -2.9% as Nomura cuts to Neutral on iPhone share https://seekingalpha.com/news/3340450-qorvominus-2_9-nomura-cuts-to-neutral-on-iphone-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3340450-qorvominus-2_9-nomura-cuts-to-neutral-on-iphone-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340449\" data-ts=\"1521555691\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340449-match-group-sues-bumble-for-patent-infringement-bumble-responds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match Group sues Bumble for patent infringement, Bumble responds</a></h4><ul><li>        Match Group&rsquo;s (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) Tinder is <a href=\"https://techcrunch.com/2018/03/16/tinder-owner-match-is-suing-bumble-over-patents/\" target=\"_blank\">suing rival Bumble</a> for patent infringement and IP misuse related to the &ldquo;card-swipe-based, mutual opt-in premise.&rdquo;</li><li>               The suit also targets Chris Gulczynski and Sarah Mick, who both left Tinder for Bumble: &ldquo;Bumble has released at least two features that its co-founders learned of and developed confidentially while at Tinder in violation of confidentiality agreements.&rdquo;&nbsp;</li><li>               Match statement to TechCrunch: &ldquo;Match Group has invested significant resources and creative expertise in the development of our industry-leading suite of products. We are committed to protecting the intellectual property and proprietary data that defines our business. Accordingly, we are prepared when necessary to enforce our patents and other intellectual property rights against any operator in the dating space who infringes upon those rights.&rdquo;&nbsp;</li><li>               Bumble <a href=\"https://techcrunch.com/2018/03/20/bumble-responds-to-matchs-patent-lawsuit/?utm_source=feedburner&amp;utm_medium=feed&amp;utm_campaign=Feed%3A+Techcrunch+%28TechCrunch%29\" target=\"_blank\">responds</a> with a full letter to Match that opens with &ldquo;We swipe left on your multiple attempts to buy us, copy us, and, now, to intimidate us.&rdquo;&nbsp;</li><li>               Key quote from the response: &ldquo;We swipe left on your attempted scare tactics, and on these endless games. We swipe left on your assumption that a baseless lawsuit would intimidate us. Given your enduring interest in our company, we expected you to know us a bit better by now.&rdquo;&nbsp;</li><li>               Match Group shares are&nbsp;<font color='green'>up 1.8%</font>&nbsp;to $46.47.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3340449\" data-linked=\"Match Group sues Bumble for patent infringement, Bumble responds\" data-tweet=\"$MTCH - Match Group sues Bumble for patent infringement, Bumble responds https://seekingalpha.com/news/3340449-match-group-sues-bumble-for-patent-infringement-bumble-responds?source=tweet\" data-url=\"https://seekingalpha.com/news/3340449-match-group-sues-bumble-for-patent-infringement-bumble-responds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340448\" data-ts=\"1521555429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WG\" target=\"_blank\">WG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340448-willbros-nears-bankruptcy-sale-sharesminus-60\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Willbros nears bankruptcy or sale; shares -60%</a></h4><ul>     <li>Willbros Group (<a href='https://seekingalpha.com/symbol/WG' title='Willbros Group, Inc.'>WG</a> <font color='red'>-62.5%</font>) plunges by more than 60% after saying it is <a href=\"https://seekingalpha.com/pr/17106058-willbros-announces-preliminary-2017-operating-results-assessing-strategic-options\" target=\"_blank\">assessing its alternatives</a>, which include selling all of its assets; seeking additional financing; or refinancing, recapitalizing or restructuring all or part of its existing debt.</li>     <li>WG says it \"began experiencing significant operating losses during [Q3] of 2017 on large lump-sum projects. The mainline pipeline project losses have continued through [Q1] of 2018 with substantial weather impacts in Q4 of 2017 and Q1 of 2018 and have adversely impacted the company&rsquo;s profitability, cash flow and liquidity.\"</li><li>WG says it is \"in advanced discussions with multiple parties regarding a sale of the company or portions of the company,\" but its expected cash on hand and  availability under its existing credit facility \"indicates a shortfall to  cover our interim operating needs.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340448\" data-linked=\"Willbros nears bankruptcy or sale; shares -60%\" data-tweet=\"$WG - Willbros nears bankruptcy or sale; shares -60% https://seekingalpha.com/news/3340448-willbros-nears-bankruptcy-sale-sharesminus-60?source=tweet\" data-url=\"https://seekingalpha.com/news/3340448-willbros-nears-bankruptcy-sale-sharesminus-60\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340446\" data-ts=\"1521554951\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TPGE.U\" target=\"_blank\">TPGE.U</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340446-tpg-pace-energy-to-buy-enervest-shale-assets-for-2_7b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TPG Pace Energy to buy EnerVest shale assets for $2.7B</a></h4><ul>     <li>TPG Pace Energy Holdings (<a href='https://seekingalpha.com/symbol/TPGE.U' title='TPG Pace Energy Holdings Corp.'>TPGE.U</a> <font color='green'>+6.3%</font>) <a href=\"https://www.bloomberg.com/news/articles/2018-03-20/tpg-pace-is-said-to-buy-enervest-shale-assets-for-2-7-billion\" target=\"_blank\">agrees to acquire</a> the oil and gas assets within EnerVest&rsquo;s South Texas Division for ~$2.66B in cash and stock, in the process forming a new publicly traded company.</li>     <li>TPGE and EnerVest will create Magnolia Oil &amp; Gas Corp., a new company led by former Occidental Petroleum CEO Steve Chazen, who will serve as Magnolia's full-time Chairman, President and CEO.</li>     <li>The partners expect the new company's stock to trade on the NYSE after the deal closes late in Q2 2018.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340446\" data-linked=\"TPG Pace Energy to buy EnerVest shale assets for $2.7B\" data-tweet=\"$TPGE.U - TPG Pace Energy to buy EnerVest shale assets for $2.7B https://seekingalpha.com/news/3340446-tpg-pace-energy-to-buy-enervest-shale-assets-for-2_7b?source=tweet\" data-url=\"https://seekingalpha.com/news/3340446-tpg-pace-energy-to-buy-enervest-shale-assets-for-2_7b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340445\" data-ts=\"1521554908\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CMCM\" target=\"_blank\">CMCM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340445-cheetah-mobileminus-1_5-on-mixed-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cheetah Mobile -1.5% on mixed Q4</a></h4><ul><li>        Cheetah Mobile (NYSE:<a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a>) trades&nbsp;<font color='red'>down 1.5%</font>&nbsp;after yesterday&rsquo;s Q4 results that beat revenue estimates but missed on EPS. Q1 guidance has revenue of RMB 1.1B to 1.4B (consensus: RMB 1.09B).</li><li>               Earnings <a href=\"https://seekingalpha.com/pr/17105091-cheetah-mobile-announces-fourth-quarter-fiscal-year-2017-unaudited-consolidated-financial\" target=\"_blank\">press release</a>.&nbsp;</li><li>               Analyst action: Nomura <a href=\"https://www.streetinsider.com/Analyst+EPS+Change/Cheetah+Mobile+%28CMCM%29%3A+Not+Out+Of+The+Woods+-+Nomura/13962945.html\" target=\"_blank\">reiterates</a> its Neutral rating and raises its Cheetah Mobile target to $12.50.&nbsp;</li><li>               Analyst Andrew Orchard says the company isn&rsquo;t out of the woods yet despite revenue growth in the core utility apps business, which remains afflicted by a number of headwinds.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340084-cheetah-mobile-misses-0_27-beats-revenue\" target=\"_blank\">Cheetah Mobile misses by $0.27, beats on revenue</a> (March 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340445\" data-linked=\"Cheetah Mobile -1.5% on mixed Q4\" data-tweet=\"$CMCM - Cheetah Mobile -1.5% on mixed Q4 https://seekingalpha.com/news/3340445-cheetah-mobileminus-1_5-on-mixed-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3340445-cheetah-mobileminus-1_5-on-mixed-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340437\" data-ts=\"1521553207\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340437-facebookminus-2_7-on-report-ftc-is-investigating-data-issue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook -2.7% on report FTC is investigating data issue</a></h4><ul>     <li>Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) is seeing another rough opening, <font color='red'>down 2.7%</font>, on fresh word that the Federal Trade Commission is investigating.</li>     <li>The FTC is now trying to determine whether the company <a href=\"https://www.bloomberg.com/news/articles/2018-03-20/ftc-to-probe-facebook-for-use-of-personal-data\" target=\"_blank\">violated terms of a consent decree</a> regarding the use of personal data, Bloomberg reports.</li>     <li>The violation at issue involves whether Facebook allowed research firm Cambridge Analytica to receive some user data in violation of its policies.</li><li>A finding of violation could mean fines of thousands of dollars per violation per day; with 50M affected users, that could <a href=\"https://twitter.com/b_fung/status/976092512673845248\" target=\"_blank\">come to $2T</a>.</li>   <li>The Digital, Culture, Media and Sport Committee of England's House of Commons has made a request of CEO Mark Zuckerberg to <a href=\"https://twitter.com/JeffMacke/status/976082651919532032\" target=\"_blank\">appear to testify</a> over user data: \"We are sure you will understand the need for a representative from right at the top of the organization to address concerns. Given your commitment at the start of the New Year to \"fixing\" Facebook, I hope that this representative will be you.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340394-facebook-plans-staff-meeting-today-discuss-data-scandal\" target=\"_blank\">Facebook plans staff meeting today to discuss data scandal</a> (Mar. 20 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340323-facebooks-auditors-stand-uk-government-request\" target=\"_blank\">Facebook's auditors stand down on UK government request</a> (Mar. 19 2018)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340317-nyt-facebook-security-chief-exiting-company-amid-disagreements\" target=\"_blank\">NYT: Facebook security chief exiting company amid disagreements</a> (Mar. 19 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340437\" data-linked=\"Facebook -2.7% on report FTC is investigating data issue\" data-tweet=\"$FB - Facebook -2.7% on report FTC is investigating data issue https://seekingalpha.com/news/3340437-facebookminus-2_7-on-report-ftc-is-investigating-data-issue?source=tweet\" data-url=\"https://seekingalpha.com/news/3340437-facebookminus-2_7-on-report-ftc-is-investigating-data-issue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340434\" data-ts=\"1521552694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DLTH\" target=\"_blank\">DLTH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340434-duluth-holdings-beats-estimates-in-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Duluth Holdings beats estimates in Q4</a></h4><ul><li>Duluth Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/DLTH' title='Duluth Holdings'>DLTH</a>) reports revenue growth of 24.8% in <a href=\"https://seekingalpha.com/filing/3943929\" target=\"_blank\">Q4</a>,&nbsp;driven by&nbsp;a&nbsp;8.5% growth in direct net sales and&nbsp;a 98.8% growth in retail net sales.</li><li>Net sales&nbsp;in&nbsp;men&rsquo;s business&nbsp;grew&nbsp;22&nbsp;% and&nbsp;women&rsquo;s business grew 37%.</li><li>The company saw 23% rise in total customers.</li><li>Gross margin rate fell 210 bps 53.3%,&nbsp;primarily&nbsp;due to&nbsp;an increase&nbsp;in global promotional days&nbsp;and flash sales&nbsp;, coupled&nbsp;with&nbsp;the continuing decline in shipping revenues.</li><li>SG&amp;A expense rate -260 bps to 39.7%.</li><li>Operating margin rate improved 50 bps to 13.6%.</li><li>Adjusted EBITDA margin increased 31.4% to $32.43M.</li><li><strong>FY2018 Guidance</strong>: Net sales: $555M to $575M; Adjusted EBITDA: $51M to $54M; Diluted EPS: $0.79 to $0.84; Tax rate: 26%; Capex: $45M to $55M; New stores: +15.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340434\" data-linked=\"Duluth Holdings beats estimates in Q4\" data-tweet=\"$DLTH - Duluth Holdings beats estimates in Q4 https://seekingalpha.com/news/3340434-duluth-holdings-beats-estimates-in-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3340434-duluth-holdings-beats-estimates-in-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340432\" data-ts=\"1521552144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GD\" target=\"_blank\">GD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340432-general-dynamics-ups-csra-offer-to-41_25-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Dynamics ups CSRA offer to $41.25/share</a></h4><ul><li>        General Dynamics (NYSE:<a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a>) increases its offer for CSRA (NYSE:<a href='https://seekingalpha.com/symbol/CSRA' title='CSRA Inc.'>CSRA</a>) to $41.25 per share in cash, up from the prior $40.75/share.</li><li>               The transaction value now stands at $9.7B including the assumption of $2.8B in CSRA debt.&nbsp;</li><li>               CSRA shares are&nbsp;<font color='green'>up 0.9%</font>&nbsp;premarket to $41.40.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340067-general-dynamics-proceed-csra-deal-despite-caci-pressure\" target=\"_blank\">General Dynamics to proceed with CSRA deal despite CACI pressure</a> (March 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340432\" data-linked=\"General Dynamics ups CSRA offer to $41.25/share\" data-tweet=\"$GD $GD $CSRA - General Dynamics ups CSRA offer to $41.25/share https://seekingalpha.com/news/3340432-general-dynamics-ups-csra-offer-to-41_25-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3340432-general-dynamics-ups-csra-offer-to-41_25-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340429\" data-ts=\"1521552086\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRPX\" target=\"_blank\">TRPX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340429-therapix-bio-on-go-to-start-mid-stage-study-of-thxminus-110-in-low-back-pain-shares-ahead-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Therapix Bio on go to start mid-stage study of THX-110 in low back pain; shares ahead 8% premarket</a></h4><ul><li>Thinly traded nano cap Therapix Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences'>TRPX</a>) is up&nbsp;<font color='green'>8%&nbsp;</font>premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/17106795-therapix-biosciences-announces-fda-clearance-investigational-new-drug-ind-phase-iia-clinical\" target=\"_blank\">announcement </a>that the FDA has signed off on its IND for THX-110&nbsp;[Dronabinol (synthetic &Delta;9-tetrahydrocannabinol) and Palmitoylethanolamide] in chronic low back pain.</li><li>A single-arm, open-label Phase 2a clinical trial should commence next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340429\" data-linked=\"Therapix Bio on go to start mid-stage study of THX-110 in low back pain; shares ahead 8% premarket\" data-tweet=\"$TRPX - Therapix Bio on go to start mid-stage study of THX-110 in low back pain; shares ahead 8% premarket https://seekingalpha.com/news/3340429-therapix-bio-on-go-to-start-mid-stage-study-of-thxminus-110-in-low-back-pain-shares-ahead-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3340429-therapix-bio-on-go-to-start-mid-stage-study-of-thxminus-110-in-low-back-pain-shares-ahead-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340428\" data-ts=\"1521551963\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IIVI\" target=\"_blank\">IIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340428-ii-viplus-3_9-b-riley-upgrades-on-growth-prospects\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">II-VI +3.9% as B. Riley upgrades on growth prospects</a></h4><ul>    <li>II-VI (NASDAQ:<a href='https://seekingalpha.com/symbol/IIVI' title='II-VI Incorporated'>IIVI</a>) has <font color='green'>gained 3.9%</font> premarket after an upgrade to Buy at B. Riley.</li>    <li>The firm's getting \"incrementally confident\" in growth prospects with Chinese demand improving \"meaningfully\" in recent weeks. Demand for industrial lasers is strong, and there are longer term growth opportunities in Silicon Carbide and 3D sensing, it says. (h/t Bloomberg)</li>    <li>It's raised its price target to $55 from $40.50, implying 21.7% upside.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340428\" data-linked=\"II-VI +3.9% as B. Riley upgrades on growth prospects\" data-tweet=\"$IIVI - II-VI +3.9% as B. Riley upgrades on growth prospects https://seekingalpha.com/news/3340428-ii-viplus-3_9-b-riley-upgrades-on-growth-prospects?source=tweet\" data-url=\"https://seekingalpha.com/news/3340428-ii-viplus-3_9-b-riley-upgrades-on-growth-prospects\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340424\" data-ts=\"1521551544\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340424-premarket-gainers-of-9-05-03-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am (03/20/2018)</a></h4><ul>     <li>CRME <font color='green'>+37%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340369-cardiome-divest-canadian-business-cipher-pharma-c-25_5m\" target=\"_blank\">divest</a> Canadian business to Cipher Pharma for C$25.5M.</li>     <li><a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+29%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340405-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a> analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a> <font color='green'>+10%</font>&nbsp;on Q4 <a href=\"https://seekingalpha.com/news/3340390-chf-solutions-reports-q4-results\" target=\"_blank\">result</a>.</li>     <li><a href='https://seekingalpha.com/symbol/MRNS' title='Marinus Pharmaceuticals'>MRNS</a> <font color='green'>+7%</font>&nbsp;on&nbsp;<a href=\"https://seekingalpha.com/news/3340405-premarket-analyst-action-healthcare\" target=\"_blank\">positive</a>&nbsp;analyst action.</li>     <li><a href='https://seekingalpha.com/symbol/TRPX' title='Therapix Biosciences'>TRPX</a> <font color='green'>+7%</font>&nbsp;as FDA has <a href=\"https://seekingalpha.com/pr/17106795-therapix-biosciences-announces-fda-clearance-investigational-new-drug-ind-phase-iia-clinical\" target=\"_blank\">cleared</a> its Investigational New Drug application for THX-110 in the treatment of Chronic Low Back Pain.</li>     <li><a href='https://seekingalpha.com/symbol/BB' title='BlackBerry Ltd.'>BB</a> <font color='green'>+5%</font>&nbsp;on enterprise <a href=\"https://seekingalpha.com/news/3340264-blackberry-plus-5-percent-enterprise-partnership-microsoft\" target=\"_blank\">partnership</a> with Microsoft.</li>     <li><a href='https://seekingalpha.com/symbol/FNJN' title='Finjan Holdings, Inc.'>FNJN</a> <font color='green'>+5%</font>&nbsp;on&nbsp;Symantec <a href=\"https://seekingalpha.com/news/3340302-finjan-plus-8_3-percent-symantec-payment\" target=\"_blank\">payment</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340424\" data-linked=\"Premarket Gainers as of 9:05 am (03/20/2018)\" data-tweet=\"$CORV $CORV $ARNA - Premarket Gainers as of 9:05 am (03/20/2018) https://seekingalpha.com/news/3340424-premarket-gainers-of-9-05-03-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340424-premarket-gainers-of-9-05-03-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340423\" data-ts=\"1521551477\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHB\" target=\"_blank\">APHB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340423-premarket-losers-of-9-05-3-20-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am (3/20/2018)</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a>&nbsp;<font color='red'>-17%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340410-ampliphi-bio-commences-direct-stock-offering-1_10-shares-16-percent-premarket\" target=\"_blank\">commencing</a> direct stock offering at $1.10..</li><li><a href='https://seekingalpha.com/symbol/NFEC' title='NF Energy Saving Corp.'>NFEC</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a>&nbsp;<font color='red'>-14%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3340320-northern-oil-gas-launch-105m-stock-offering\" target=\"_blank\">announcing</a> a&nbsp;public offering&nbsp;of $105M of common shares.</li><li><a href='https://seekingalpha.com/symbol/ALO' title='Alio Gold Inc'>ALO</a> <font color='red'>-14%</font>.</li><li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a>&nbsp;<font color='red'>-11%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340266-proteostasis-launches-9m-share-stock-offering\" target=\"_blank\">initiating</a> a public offering of 9M shares of common stock.</li><li><a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340260-oracle-beats-0_11-revenue-line\" target=\"_blank\">Q3 earrnings</a>.</li><li><a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3340348-childrens-place-retail-stores-beats-0_03-misses-revenue\" target=\"_blank\">Q4 earrnings</a>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3340423\" data-linked=\"Premarket Losers as of 9:05 am (3/20/2018)\" data-tweet=\"$APHB $ARMP $BIMI - Premarket Losers as of 9:05 am (3/20/2018) https://seekingalpha.com/news/3340423-premarket-losers-of-9-05-3-20-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3340423-premarket-losers-of-9-05-3-20-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340422\" data-ts=\"1521551318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDXG\" target=\"_blank\">IDXG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340422-interpace-up-6-premarket-on-new-labcorp-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpace up 6% premarket on new LabCorp deal</a></h4><ul><li>Interpace Diagnostics (NASDAQ:<a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on average volume on the heels of its <a href=\"https://seekingalpha.com/pr/17106623-interpace-diagnostics-announces-expansion-labcorp-national-agreement\" target=\"_blank\">announcement </a>of a new agreement with LabCorp (NYSE:<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a>) aimed at expanding its nationwide network of cytology providers supporting its ThyGenX and ThyraMIR tests.</li><li>Under the terms of the new contract, which builds on the original agreement inked in 2016, doctors will be able to order both thyroid biopsy analysis and molecular testing from Interpace. LabCorp's Dianon Pathology will perform the biopsy analysis and, if the result is inconclusive, Interpace will perform its molecular tests. Doctors may also request an automatic reflex to the molecular tests when they submit a biopsy sample.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340422\" data-linked=\"Interpace up 6% premarket on new LabCorp deal\" data-tweet=\"$IDXG $IDXG $LH - Interpace up 6% premarket on new LabCorp deal https://seekingalpha.com/news/3340422-interpace-up-6-premarket-on-new-labcorp-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3340422-interpace-up-6-premarket-on-new-labcorp-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:08 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340417\" data-ts=\"1521550688\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HAIR\" target=\"_blank\">HAIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340417-fda-clears-expanded-use-for-restoration-robotics-artas-shares-up-13-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears expanded use for Restoration Robotics&#39; ARTAS; shares up 13% premarket</a></h4><ul><li>Thinly traded micro cap Restoration Robotics (NASDAQ:<a href='https://seekingalpha.com/symbol/HAIR' title='Restoration Robotics'>HAIR</a>) is up&nbsp;<font color='green'>13%</font>&nbsp;premarket, albeit on only 200 shares, in response to its <a href=\"https://seekingalpha.com/pr/17106707-restoration-robotics-receives-us-fda-510-k-clearance-implantation-function\" target=\"_blank\">announcement </a>that the FDA has granted 510(k) clearance to use its ARTAS Robotic Hair Restoration System for implanting hair follicles. The company says it expects to offer the additional functionality by year-end.</li><li><a href=\"http://www.restorationrobotics.com/artas-harvesting/\" target=\"_blank\">ARTAS </a>was originally cleared for harvesting hair follicles.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340417\" data-linked=\"FDA clears expanded use for Restoration Robotics&#39; ARTAS; shares up 13% premarket\" data-tweet=\"$HAIR $VERO - FDA clears expanded use for Restoration Robotics&#39; ARTAS; shares up 13% premarket https://seekingalpha.com/news/3340417-fda-clears-expanded-use-for-restoration-robotics-artas-shares-up-13-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3340417-fda-clears-expanded-use-for-restoration-robotics-artas-shares-up-13-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340412\" data-ts=\"1521549929\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340412-bofaml-adds-qualcomm-to-us-1-list\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BofAML adds Qualcomm to US 1 List</a></h4><ul><li>        Bank of America Merrill Lynch <a href=\"https://www.streetinsider.com/Analyst+Comments/Qualcomm+%28QCOM%29+Added+to+BofAMerrill+Lynch+US+1+List/13962315.html\" target=\"_blank\">adds</a> Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>) to its US 1 List and sets a $75 price target, a 28% upside to yesterday&rsquo;s close.</li><li>                  Analyst Tal Liani cites the potential for catalysts and &ldquo;big changes.&rdquo;    </li><li>               Qualcomm shares are&nbsp;<font color='green'>up 1.1%</font>&nbsp;premarket to $59.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3340412\" data-linked=\"BofAML adds Qualcomm to US 1 List\" data-tweet=\"$QCOM - BofAML adds Qualcomm to US 1 List https://seekingalpha.com/news/3340412-bofaml-adds-qualcomm-to-us-1-list?source=tweet\" data-url=\"https://seekingalpha.com/news/3340412-bofaml-adds-qualcomm-to-us-1-list\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>44&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340410\" data-ts=\"1521549682\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/APHB\" target=\"_blank\">APHB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340410-ampliphi-bio-commences-direct-stock-offering-1_10-shares-down-16-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmpliPhi Bio commences direct stock offering at $1.10; shares down 16% premarket</a></h4><ul><li>AmpliPhi Biosciences (NYSEMKT:<a href='https://seekingalpha.com/symbol/APHB' title='AmpliPhi Biosciences Corp.'>APHB</a>) slumps&nbsp;<font color='red'>16%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/17106559-ampliphi-biosciences-announces-registered-direct-offering-common-stock\" target=\"_blank\">direct offering</a> of ~2.7M shares of common stock at $1.10 per share to certain institutional investors. Net proceeds will be used for general corporate purposes.</li><li>Closing date is March 22.</li><li>Yesterday's close was $1.54.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340410\" data-linked=\"AmpliPhi Bio commences direct stock offering at $1.10; shares down 16% premarket\" data-tweet=\"$APHB $ARMP - AmpliPhi Bio commences direct stock offering at $1.10; shares down 16% premarket https://seekingalpha.com/news/3340410-ampliphi-bio-commences-direct-stock-offering-1_10-shares-down-16-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3340410-ampliphi-bio-commences-direct-stock-offering-1_10-shares-down-16-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340408\" data-ts=\"1521549599\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ROKU\" target=\"_blank\">ROKU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340408-roku-up-5_2-opco-upgrades\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Roku up 5.2% as Opco upgrades</a></h4><ul>     <li>Oppenheimer upgrades Roku (NASDAQ:<a href='https://seekingalpha.com/symbol/ROKU' title='Roku Inc.'>ROKU</a>) to perform from underperform following the stock's big decline. \"The stock is now within 1% of our $33 PT (now removed) and no longer appears to be a compelling short.\"</li><li>In other news, The Roku Channel, an AVOD app <a href=\"https://seekingalpha.com/pr/17106635-b-roku-b-channel-available-app-select-samsung-smart-tvs-u-s-summer\" target=\"_blank\">is expected to be</a> available this summer on select Samsung smart TVs.</li>     <li>Shares <font color='green'>+5.2%</font> PM.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340408\" data-linked=\"Roku up 5.2% as Opco upgrades\" data-tweet=\"$ROKU - Roku up 5.2% as Opco upgrades https://seekingalpha.com/news/3340408-roku-up-5_2-opco-upgrades?source=tweet\" data-url=\"https://seekingalpha.com/news/3340408-roku-up-5_2-opco-upgrades\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340407\" data-ts=\"1521549502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASH\" target=\"_blank\">ASH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340407-ashland-to-explore-options-for-composites-unit-german-facility\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ashland to explore options for composites unit, German facility</a></h4><ul>     <li>Ashland (NYSE:<a href='https://seekingalpha.com/symbol/ASH' title='Ashland Inc.'>ASH</a>)&nbsp;<font color='green'>+3%</font> premarket after saying it will <a href=\"http://investor.ashland.com/releasedetail.cfm?ReleaseID=1061435\" target=\"_blank\">explore strategic alternatives</a>, including a potential sale, for its composites segment and its butanediol manufacturing facility in Marl, Germany.</li>     <li>ASH says it will retain its butanediol plant in Lima,  Ohio, to ensure consistent supply for the company's internal needs.</li>     <li>The company says it plans to use the proceeds of any deal for debt reduction and stock buybacks.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3340407\" data-linked=\"Ashland to explore options for composites unit, German facility\" data-tweet=\"$ASH - Ashland to explore options for composites unit, German facility https://seekingalpha.com/news/3340407-ashland-to-explore-options-for-composites-unit-german-facility?source=tweet\" data-url=\"https://seekingalpha.com/news/3340407-ashland-to-explore-options-for-composites-unit-german-facility\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:38 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340398\" data-ts=\"1521549031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRIL\" target=\"_blank\">TRIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340398-trillium-therapeutics-ttiminus-621-orphan-drug-in-u-s-for-t-cell-lymphoma-shares-ahead\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trillium Therapeutics&#39; TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead</a></h4><ul><li>Trillium Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/17106419-trillium-therapeutics-ttiminus-621-receives-orphan-drug-designation-treatment-cutaneous-t\" target=\"_blank\">announcement </a>that the FDA has designated TTI-621 an Orphan Drug for the treatment of cutaneous T-cell lymphoma.</li><li>Phase 1-stage&nbsp;<a href=\"http://trilliumtherapeutics.com/pipeline/tti-621/default.aspx\" target=\"_blank\">TTI-621</a> is a fusion protein that activates the innate immune system by blocking the activity of a protein found on the surface of cancer cells called CD47 which allows them to avoid detection by immune cells.</li><li>Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340398\" data-linked=\"Trillium Therapeutics&#39; TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead\" data-tweet=\"$TRIL - Trillium Therapeutics&#39; TTI-621 an Orphan Drug in U.S. for T-cell lymphoma; shares ahead https://seekingalpha.com/news/3340398-trillium-therapeutics-ttiminus-621-orphan-drug-in-u-s-for-t-cell-lymphoma-shares-ahead?source=tweet\" data-url=\"https://seekingalpha.com/news/3340398-trillium-therapeutics-ttiminus-621-orphan-drug-in-u-s-for-t-cell-lymphoma-shares-ahead\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340395\" data-ts=\"1521548248\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KMPH\" target=\"_blank\">KMPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340395-kempharm-reports-positive-results-from-pk-study-of-adhd-candidate-kp415\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KemPharm reports &quot;positive&quot; results from PK study of ADHD candidate KP415</a></h4><ul><li>Thinly traded nano cap KemPharm (NASDAQ:<a href='https://seekingalpha.com/symbol/KMPH' title='KemPharm'>KMPH</a>) is up&nbsp;<font color='green'>6%</font>&nbsp;premarket, albeit on only 280 shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17106453-kempharm-announces-positive-topline-results-kp415-pharmacokinetic-study-children-adolescents\" target=\"_blank\">announcement </a>of topline data from an ongoing pharmacokinetic &#40;PK&#41; study of KP415 in pediatric and adolescent patients with attention-deficit/hyperactivity disorder &#40;ADHD&#41;.</li><li>The company says oral administration of KP415 resulted in predictable exposure to the active ingredient d-methylphenidate which it says may allow for a single efficacy study in the classroom ADHD trial design in pediatrics without \"pediatric only\" labeling.</li><li>Topline results from the ongoing pivotal study KP415.E01 should be available mid-year.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340395\" data-linked=\"KemPharm reports &quot;positive&quot; results from PK study of ADHD candidate KP415\" data-tweet=\"$KMPH - KemPharm reports &quot;positive&quot; results from PK study of ADHD candidate KP415 https://seekingalpha.com/news/3340395-kempharm-reports-positive-results-from-pk-study-of-adhd-candidate-kp415?source=tweet\" data-url=\"https://seekingalpha.com/news/3340395-kempharm-reports-positive-results-from-pk-study-of-adhd-candidate-kp415\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340394\" data-ts=\"1521548132\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340394-facebook-plans-staff-meeting-today-to-discuss-data-scandal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Facebook plans staff meeting today to discuss data scandal</a></h4><ul><li>        <a href=\"https://www.theverge.com/2018/3/20/17142074/facebook-employee-meeting-cambridge-analytica\" target=\"_blank\">The Verge</a> reports that Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) will hold an open employee meeting to deal with the fallout from the Cambridge Analytica data scandal.</li><li>               Deputy general counsel Paul Grewal will lead the meeting, which starts at 10 AM PT and is scheduled to last 30 minutes.&nbsp;&nbsp;</li><li>               A Mark Zuckerberg-led meeting is expected to happen on Friday.&nbsp;</li><li>               Facebook shares are&nbsp;<font color='red'>down 0.3%</font>&nbsp;premarket to $172.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340317-nyt-facebook-security-chief-exiting-company-amid-disagreements\" target=\"_blank\">NYT: Facebook security chief exiting company amid disagreements</a> (March 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340394\" data-linked=\"Facebook plans staff meeting today to discuss data scandal\" data-tweet=\"$FB - Facebook plans staff meeting today to discuss data scandal https://seekingalpha.com/news/3340394-facebook-plans-staff-meeting-today-to-discuss-data-scandal?source=tweet\" data-url=\"https://seekingalpha.com/news/3340394-facebook-plans-staff-meeting-today-to-discuss-data-scandal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340390\" data-ts=\"1521547471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CHFS\" target=\"_blank\">CHFS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340390-chf-solutions-reports-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">CHF Solutions reports Q4 results</a></h4><ul><li>CHF Solutions (NASDAQ:<a href='https://seekingalpha.com/symbol/CHFS' title='CHF Solutions, Inc.'>CHFS</a>): Q4 EPS of -$10.00</li><li>Revenue of $0.83M (+10.7% Y/Y)</li><li>Shares <font color='green'>+17.5%</font> PM.</li><li><a href='https://seekingalpha.com/pr/17106545-chf-solutions-inc-announces-11_4-percent-revenue-growth-fourth-quarter-provides-company'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3340390\" data-linked=\"CHF Solutions reports Q4 results\" data-tweet=\"$CHFS - CHF Solutions reports Q4 results https://seekingalpha.com/news/3340390-chf-solutions-reports-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3340390-chf-solutions-reports-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340374\" data-ts=\"1521545055\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ORCL\" target=\"_blank\">ORCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340374-oracle-q4-guidance-features-cloud-disappointment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oracle Q4 guidance features cloud disappointment</a></h4><ul><li>        Oracle&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/ORCL' title='Oracle Corporation'>ORCL</a>) Q4 guidance has revenue growing 1% to 3% on last year&rsquo;s $10.94B compared to the $11.22B consensus. Growth expected flat to -2% in constant currency.</li><li>               EPS guided from $0.92 to $0.95 in USD and $0.89 to $0.92 in constant currency (consensus: $0.90).&nbsp;</li><li>               Cloud revenues including SaaS, PaaS, and IaaS expected to grow 19% to 23% in USD or 17% to 21% in constant currency. Analysts expected a 23% total cloud growth. &nbsp;&nbsp;</li><li>               Earnings call <a href=\"https://seekingalpha.com/article/4157663-oracles-orcl-ceo-safra-catz-mark-hurd-q3-2018-results-earnings-call-transcript?part=single\" target=\"_blank\">transcript</a>.&nbsp;</li><li>               Oracle shares are&nbsp;<font color='red'>down 8.5%</font>&nbsp;premarket to $47.55 with a 52-week range $43.60 to $53.48.&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3340281-oracle-minus-2_6-percent-q3-line-revenue-32-percent-cloud-revenue-growth\" target=\"_blank\">Oracle -2.6% on Q3 in-line revenue, 32% cloud revenue growth</a> (March 19)</li></ul> &nbsp;<br /><div class=\"tiny-share-widget\" data-id=\"3340374\" data-linked=\"Oracle Q4 guidance features cloud disappointment\" data-tweet=\"$ORCL - Oracle Q4 guidance features cloud disappointment https://seekingalpha.com/news/3340374-oracle-q4-guidance-features-cloud-disappointment?source=tweet\" data-url=\"https://seekingalpha.com/news/3340374-oracle-q4-guidance-features-cloud-disappointment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340369\" data-ts=\"1521544397\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340369-cardiome-to-divest-canadian-business-to-cipher-pharma-for-c-25_5m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiome to divest Canadian business to Cipher Pharma for C$25.5M</a></h4><ul><li>Cardiome Pharma (CRME) has <a href=\"https://seekingalpha.com/pr/17106402-cipher-pharmaceuticals-cardiome-pharma-announce-strategic-transaction-canadian-business\" target=\"_blank\">agreed to sell </a>its Canadian business to Cipher Pharmaceuticals (CPHR) for C$25.5M in cash. The acquired assets include Brinavess (vernakalant IV), Aggrastat (tirofiban hydrochloride), Xydalba (dalbavancin hydrochloride) and Trevyent.</li><li>The transaction will be completed following Cipher's acquisition of all the outstanding shares of Cardiome on a one-to-one basis.&nbsp;The combined Canadian organization will do business as Correvio Pharma and will apply for listing on Nasdaq and the Toronto Stock Exchange &#40;TSX&#41;.</li><li><strong>Update</strong>: Shares are up&nbsp;<font color='green'>12%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340369\" data-linked=\"Cardiome to divest Canadian business to Cipher Pharma for C$25.5M\" data-tweet=\"$CORV $CORV $CPHRF - Cardiome to divest Canadian business to Cipher Pharma for C$25.5M https://seekingalpha.com/news/3340369-cardiome-to-divest-canadian-business-to-cipher-pharma-for-c-25_5m?source=tweet\" data-url=\"https://seekingalpha.com/news/3340369-cardiome-to-divest-canadian-business-to-cipher-pharma-for-c-25_5m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340367\" data-ts=\"1521543757\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNMX\" target=\"_blank\">SNMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340367-senomyx-hires-advisors-in-review-of-strategic-alternatives\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Senomyx hires advisors in review of strategic alternatives</a></h4><ul><li>Thinly traded nano cap Senomyx (NASDAQ:<a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a>) has <a href=\"https://seekingalpha.com/pr/17106368-senomyx-engages-needham-and-company-conexus-capital-advisors-explore-strategic-alternatives\" target=\"_blank\">retained </a>Needham &amp; Company and Conexus Capital Advisors to review and assess strategic alternatives aimed at boosting shareholder value, including a possible sale of the company.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340367\" data-linked=\"Senomyx hires advisors in review of strategic alternatives\" data-tweet=\"$SNMX - Senomyx hires advisors in review of strategic alternatives https://seekingalpha.com/news/3340367-senomyx-hires-advisors-in-review-of-strategic-alternatives?source=tweet\" data-url=\"https://seekingalpha.com/news/3340367-senomyx-hires-advisors-in-review-of-strategic-alternatives\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340365\" data-ts=\"1521543502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CORV\" target=\"_blank\">CORV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340365-cardiome-halted-for-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cardiome halted for pending news</a></h4><ul><li>Nasdaq has suspended trading in Cardiome Pharma (CRME) pending the release of news.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340365\" data-linked=\"Cardiome halted for pending news\" data-tweet=\"$CORV - Cardiome halted for pending news https://seekingalpha.com/news/3340365-cardiome-halted-for-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3340365-cardiome-halted-for-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340364\" data-ts=\"1521543209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ARNA\" target=\"_blank\">ARNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340364-arena-pharmas-etrasimod-successful-in-mid-stage-uc-study-shares-up-20-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Arena Pharma&#39;s etrasimod successful in mid-stage UC study; shares up 20% premarket</a></h4><ul><li>A <a href=\"https://clinicaltrials.gov/ct2/show/NCT02447302?intr=etrasimod&amp;lead=arena+pharmaceuticals&amp;phase=1&amp;rank=3\" target=\"_blank\">Phase 2 clinical trial</a> evaluating Arena Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/ARNA' title='Arena Pharmaceuticals, Inc.'>ARNA</a>) etrasimod in ulcerative colitis &#40;UC&#41; patients <a href=\"https://seekingalpha.com/pr/17106018-arena-pharmaceuticals-reports-positive-phase-2-results-oasis-trial-etrasimod-patients\" target=\"_blank\">met all primary </a>and secondary endpoints.</li><li>The study met the primary endpoint of demonstrating a statistically significant improvement in three-component Mayo Clinic Score versus placebo at week 12 for the 2 mg dose of etrasimod (p=0.009). The effect for the 1 mg dose was not statistically valid (p=0.146).</li><li>The proportion of patients in the 2 mg cohort who achieved endoscopic improvement was statistically significantly greater than placebo (41.8% vs. 17.8%; p=0.003).</li><li>The proportion of patients in the 2 mg cohort who achieved clinical remission was also statistically significant compared to placebo (33.0% vs. 8.1%; p=0.004).</li><li>On the safety front, etrasimod was well-tolerated with no new safety signals reported. There were no serious adverse events observed in the 2 mg cohort compared to 11.1% for placebo. The impact on heart rate and <a href=\"https://en.ecgpedia.org/wiki/AV_Conduction\" target=\"_blank\">atrioventricular &#40;AV&#41; conduction</a> (impairment of electrical continuity between the atria and ventricles) was low throughout the study with no discontinuations due to bradycardia (low heart rate) or AV block.</li><li>Complete results will be submitted for presentation at future medical conferences.</li><li>The company plans to advance etrasimod into Phase 3 development.</li><li>Etrasimod (APD334) is an orally available next-generation sphingosine 1-phosphate (S1P) receptor modulator. Selected binding to subtype S1PR1 leads to anti-inflammatory activity by its (theorized) interference with the migration of a specific subset of activated lymphocytes to sites of inflammation.</li><li>Shares are up&nbsp;<font color='green'>20%</font>&nbsp;premarket on light volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3311179-arena-completes-enrollment-mid-stage-etrasimod-study-uc-shares-1-percent\" target=\"_blank\">Arena completes enrollment in mid-stage etrasimod study in UC; shares up 1%</a> (Nov. 10, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3340364\" data-linked=\"Arena Pharma&#39;s etrasimod successful in mid-stage UC study; shares up 20% premarket\" data-tweet=\"$ARNA - Arena Pharma&#39;s etrasimod successful in mid-stage UC study; shares up 20% premarket https://seekingalpha.com/news/3340364-arena-pharmas-etrasimod-successful-in-mid-stage-uc-study-shares-up-20-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3340364-arena-pharmas-etrasimod-successful-in-mid-stage-uc-study-shares-up-20-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:53 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3340362\" data-ts=\"1521542498\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLCE\" target=\"_blank\">PLCE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3340362-on-childrens-place-retail-stores-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Children&#39;s Place Retail Stores&#39; Q4 results</a></h4><ul><li>Children's Place Retail Stores (NASDAQ:<a href='https://seekingalpha.com/symbol/PLCE' title='The Children&#39;s Place Retail Stores, Inc.'>PLCE</a>) reports comparable retail sales rose 8.2%&nbsp;in <a href=\"https://seekingalpha.com/pr/17106342-children-s-place-sets-12-percent-operating-margin-12_00-eps-targets-fiscal-2020-enabled\" target=\"_blank\">Q4</a>.</li><li>Adjusted gross margin rate improved 90 bps to 37%, driven by the leverage of fixed expenses resulting from the strong comparable retail sales and merchandise margin expansion.</li><li>Adjusted SG&amp;A expense rate slipped 30 bps to 23.6%.</li><li>Adjusted operating margin rate expanded 40 bps to 10%.</li><li>Store count -25 Y/Y to 1,014.</li><li><b>Q1 Guidance</b>: Comparable retail sales:&nbsp;low single digit increase; Adjusted EPS: $2.12 to $2.22.</li><li><b>FY2018 Guidance</b>: Comparable retail sales: ~+2.5% to +3.5%; Adjusted EPS: $7.95 to $8.20.</li><li>PLCE&nbsp;<font color='green'>+0.40%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3340362\" data-linked=\"More on Children&#39;s Place Retail Stores&#39; Q4 results\" data-tweet=\"$PLCE - More on Children&#39;s Place Retail Stores&#39; Q4 results https://seekingalpha.com/news/3340362-on-childrens-place-retail-stores-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3340362-on-childrens-place-retail-stores-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:41 AM </div></div></li>","count":73,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}